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ABSTRACT

The psrt mutations, 723SJ and 1060SJ, are END-induced, non-complementing
mutations that produce identical phenotypes and map to the same p-deletion interval on
mouse chromosome 7. psrt stand for profound seizure and runting; animals exhibiting
this phenotype are runted and have severe seizures that are first detected at seven to ten
days of age. Homozygous and hemizygous mutants typically live 15 to 18 days. A
positional cloning strategy was employed to identify the gene responsible for this
phenotype. The region of the genome containing psrt was better defined by mapping

3ooH,a p-deletion that does
molecular markers and determining the breakpoints of p3RD
not complement the phenotype.

A physical map was constructed in the minimal

deletion interval determined to contain the mutation, and a Bacterial Artificial
Chromosome from the physical map was sequenced to identify candidate genes. Three
genes were identified, two from sequence analysis (Tat-interacting protein (30 kDa),
Tip30, and protein arginine N-methyltransferase 3, Prmt3) and one from a search of the

genome sequencing databases from the human region of homology (glycine transporter
type 2, GLYT2).

No mutations were detected in the Tip30 cDNA and G/yt2 was not

molecularly characterized. However, the 5' end of the 723SJ Prmt3 transcript could not
be amplified, indicating a possible chromosomal rearrangement or deletion, and
mutation screening by temperature-gradient capillary electrophoresis was utilized to
detect mismatches between the control and both the 723SJ and 1060SJ cDNAs. This
indicates that mutations in the Prmt3 transcript are present in both strains of mutants.

lV

Initial sequence analysis failed to detect a mutation; however, further sequencing will
be performed to verify the mismatches.

Since Prmt3 could be involved in the

methylation of the single methylarginine residue in the myelin basic protein, an assay to
detect the presence of this residue in the myelin basic protein hydrolysate was
performed on mutants and controls from the 1060SJ strain of mice. Results indicate
that the methylarginine is easily detected in the 1060SJ control animals, but could not
be detected in the 1060SJ psrt mutants. The molecular and biochemical evidence
suggests that Prmt3 is the gene responsible for the psrt phenotype.
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CHAPTER!
OVERVIEW OF THE PROJECT ~TI DESCRIPTION OF THE psrt PHENOTYPE

OVERVIEW
This dissertation documents the positional cloning of the gene responsible for
the profound seizure and runting (psrt) phenotype on mouse chromosome 7. Chapter
one contains an overview of the project and a description of the phenotype. Chapter two
contains the background information on the genetic reagents utilized in this project as
well as the methodology utilized to produce the mutants.

Chapter three contains a

summary of the trans-complementation data that allowed the mutation to be finemapped. Chapters four, five, seven and eight contain experimental data and include
five major sections:
discussion.

abstract, introduction, materials and methods, results, and

Chapter four covers physical mapping in the psrt region, chapter five

covers the sequence analysis of genomic clones in the region, chapter seven covers an
expression analysis of candidate genes and a sequence analysis of their transcripts, and
chapter eight covers the analysis of methylarginine in the myelin basic protein of
mutant and control animals. Chapter six consists of a detailed literature review of the
candidate genes and Chapter nine is an evaluation of the candidates. Chapter ten, the
final chapter, is a brief assessment of future work that is needed to give closure to the
project.

Literature references and an appendix containing the tables, figures and

legends follow the ten chapters.

1

THE psrt PHENOTYPE
This project undertook the positional cloning of the gene responsible for a
juvenile lethal, neurological phenotype called psrt, for "profound seizure and runting."
As the name implies, this phenotype manifests as severe seizures and runting. The
seizures, characterized by stiffened and extended limbs, are first detected in the mutants
at around seven to ten days after birth.

Seizure activity increases in intensity and

duration until the animal eventually dies, at around 15-18 days. Mutants can easily be
distinguished from their non-mutant littermates by their runted appearance, even at
birth. Their development appears to be delayed, since not only are they smaller in size,
but also their fur is sparse and slow to come in. This runtedness is not due to starvation
because milk is visible in the pups' stomachs, even after the onset of seizure activity
and up until the time of death.

2

CHAPTER II
BACKGROUND

INTRODUCTION
This research was performed using mutant animals generated over the years in
the mutagenesis programs at the Oak Ridge National Laboratory (ORNL).

What

follows is a brief overview of the development of the genetic and molecular reagents
utilized in these mutagenesis studies as well as a description of the mutagenesis
programs themselves.

THE SPECIFIC LOCUS TEST (SLT)
The morphological specific locus test (SLT) was developed in the late 1940s by
William L. (Bill) Russell at the ORNL to investigate the induction of heritable
mutations in the mammalian germline by ionizing radiation (Russell, 1951). To enable
the recovery of new recessive mutations, Russell constructed the mouse T (tester) stock,
which is homozygous for then-existing recessive alleles at seven loci that code for
visible phenotypes in the mouse. The seven loci, located on five chromosomes, include
six that affect coat color and one that affects ear morphology.

The recessive T-stock

alleles at three unlinked loci are: non-agouti (a) at the a locus on chromosome 2; brown
(b; Tyrplb) at the tyrosine-related protein (Tyrpl) locus on chromosome 4; and piebald

spotting (s; Ednrb 5) at the endothelin receptor type B (Ednrb) locus on chromosome 14.
Alleles at two sets of linked loci are: pink-eyed dilution (p) at the p locus and chinchilla
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(cc\ Tyre-ch)at the Tyrosinase (Tyr) locus, 15 centimorgans (cM) apart on chromosome

7; and dilute (d; Myo5ad) at the myosin SA (Myo5a) locus and short-ear (se; Bmp5se) at
the bone morphogenetic protein 5 (Bmp5) locus, 0.16 cM apart on chromosome 9
(Russell, 1951).
The SLT is performed by exposing mice that are homozygous wild type at all
seven specific loci to a potential mutagen, then mating them to T-stock animals. If no
new mutations are induced at any of the seven loci, all offspring of this mating are
phenotypically wild type; however, if one or more recessive mutations were generated
at any of the seven loci, mutant animals would be detected in the first-generation of
offspring. Dominant visible mutations induced anywhere in the genome are detectable.
If a newly induced mutation at one of the specific loci is lethal, this new mutation can

still be recovered in lines derived from the heterozygous primary F 1 mutant by
appropriate breeding, and can be perpetuated in a stock. The beauty of the SLT is
threefold: since the loci affect coat color and ear morphology, the mutants are easily,
quickly, and objectively recognized and categorized by their physical appearance; the
mutations can be detected in only one generation; and all mutations, including any that
are recessive lethals, can be recovered and perpetuated (Russell, 1951).
The SLT was initially used at the Oak Ridge National Laboratory to ascertain
the rate of induction of heritable mutations by ionizing radiations in mouse germ cells,
and, specifically, the effects of various physical and biological variables on the
frequency and nature of the induced mutations.

This information was desperately

needed, since the effects of ionizing radiation on the human germ line were unknown at
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the time. The only other organisms in which radiation-mutagenesis studies had been
performed at that time were maize, Zea mais, and the fruit fly, Drosophila
melanogaster; however, Russell felt that data from mammalian species were necessary

because they would more closely estimate the effect on humans. He designed the SLT
primarily to give quantitative data by measuring the mutation rate at each of the seven
loci. However, he also designed the SLT to give qualitative information about the
mutations emerging from the studies, since two of the loci are very tightly linked (d and
se are a mere 0.16 cM apart on chromosome 9) and a point mutation or intragenic lesion

would affect only one of the two loci while a deletion might affect both loci (Russell,
1951).
Because the SLT measured mutation rates at each of the specific loci, Russell
was able to conclude early in his work that genes vary greatly in their mutability
(Russell, 1951). Bill and Liane B. (Lee) Russell determined that chronic doses of
radiation produced fewer detectable mutations in spermatogonial stem cells (Russell et
al., 1958) and in oocytes (reviewed in Russell and Russell, 1992) than the same amount

of radiation administered in a single, acute dose, providing early evidence for repair of
premutational damage (Russell et al., 1958). They also used the SLT to study the
genetic effects of numerous chemical mutagens. These experiments revealed that the
stage at which germ-cells were exposed had a profound effect not only on the frequency
but on the nature of the induced mutations (reviewed in Russell et al. 1990, Russell,
2001). One of the chemicals investigated, N-ethyl-N-nitrosourea (ENU), was found to
be by far the most effective mutagen identified in the mouse (Russell et al., 1979b;
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Russell et al., 1981). Their work revealed that with ENU, as with radiation, there are
DNA repair mechanisms active in mouse germ cells (Russell et al., 1982b; Russell et

al., 1982c).
An SLT utilizing a different test stock was conducted by a Medical Research
Council group at Harwell, England. This test stock carried homozygous recessives at
six specific loci, namely: fuzzy (ft) and leaden (In) on chromosome 1; brachypody (bp;
growth differentiation factor 5, Gdf5), nonagouti (a), and pallid (pa; Pallidin, Pldn) on
chromosome 2; and pearl (pe; beta-3A adaptin, Ap3bl) on chromosome 13. Because of
the selection of a different set of specific loci from those in the Russell T stock, the
Harwell data indicated a slightly different average mutation rate from that calculated by
the Russells (Lyon and Morris, 1966). However, their conclusions were identical to
those drawn from the work at Oak Ridge:

ionizing radiation induces heritable

mutations in mammals at a higher rate than it does in Drosophila melanogaster
(Russell, 1951; Lyon and Morris, 1966).

DELETION COMPLEXES IN THE MOUSE GENOME
The radiation mutagenesis work at ORNL led to the isolation of numerous
mutations at the seven specific loci. Molecular and genetic analyses of mice carrying
these mutations led to the conclusion that many of the mutations are chromosomal
deletions of varying sizes. Crosses between pairs of mutants at each locus, followed by
a detailed phenotypic analysis of the progeny of these crosses, led to the identification
of complementation groups. Subsequent molecular analysis within complementation
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groups has allowed each family of deletions to be ordered into a deletion complex,
consisting of a set of nested and overlapping deletions (reviewed in Russell and
Rinchik, 1987 and Russell, 1989; O'Brien et al., 1996). In addition to those generated
at ORNL, deletion complexes have been produced by other groups at some of the same
(i.e. the pink-eyed dilution) and other loci. These mutations have been induced through
mutagenesis schemes utilizing either ionizing radiation in mice (Lyon and Morris,
1966) or embryonic stem (ES) cells (You et al., 1997; Thomas et al. 1998; Schimenti et
al., 2000), or Cre-LoxP recombination in ES cells (Ramirez-Solis et al., 1995).

Deletion complexes have proven to be an invaluable reagent in the genetic and
molecular analysis of the regions of the genome that they cover. Crosses between
carriers of different deletions within the same complex are used to identify regions of
the genome (called complementation groups) that are associated with a particular
phenotype by examining the offspring of such crosses to determine what "functions" are
missing. The missing "function(s)" must map to the region of the genome deleted by
the overlap of the two deletions (Rinchik and Russell, 1987; Rinchik and Russell,
1990).

Such genetic, or complementation, analyses have been used to identify

complementation groups in the brown (b) region of chromosome 4 (Rinchik, 1994), the
albino (c) region of chromosome 7 (Gluecksohn-Waelsch, 1979; Russell et al., 1982a;
Russell et al., 1979a; Niswander et al., 1988; Russell, 1979; Russell and Raymer, 1979,
Rinchik and Carpenter, 1999), the pink-eyed dilution (p) region of chromosome 7 (Lyon
et al., 1992; Russell et al., 1995), the dilute-short ear (d-se) region of chromosome 9

(Russell, 1971), and the piebald (s) region of chromosome 14 (O'Brien et al., 1996).
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Perhaps the most valuable use of the deletion complexes is as a reagent for finestructural mapping by crossing an animal that is either homozygous (carrying two
copies of a single allele) or heterozygous (containing two different alleles) for the
recessive trait to be mapped to animals carrying chromosomal deletions from the
genomic region of interest.

If the recessive phenotype maps within the deletion being

tested, then the hemizygous offspring (containing a single allele opposite a deletion)
exhibit the recessive phenotype. If the recessive phenotype does not map within the
deletion being tested, then the offspring are heterozygous and exhibit a wild-type
phenotype

(reviewed m Rinchik and Russell,

complementation

1990).

These types of trans-

crosses have been used extensively to map numerous recessive

phenotypes and genes to various deletions, including the albino (c) deletion complex on
chromosome 7 (Russell et al., 1982a; Rinchik et al., 1993b; Potter and Rinchik, 1993;
Potter et al., 1995; Rinchik and Carpenter, 1993 and 1999), the p deletion complex on
chromosome 7 (Culiat et al., 1993), the Krd deletion on chromosome 19 (Ji et al.,
1999), and the Brachyury (1) deletion complex on chromosome 17 (Bergstrom et al.,
1998).
The deletion complexes can also be used to fine-map molecular markers and
probes relative to the deletion breakpoints. This is accomplished through the use of
panels of DNAs from F 1 hybrids of an interspecific cross, e.g. Mus musculus X Mus

spretus cross, with the chromosomal deletion of interest carried on the Mus musculus
chromosome.

Taking advantage of the high rate of polymorphism between the Mus

musculus and related Mus species (Silver, 1995), any molecular probe showing a

8

restriction fragment length polymorphism (RFLP) between two species can be used for
mapping. If the probe maps within the deletion being tested, then the hybridization
band corresponding to the Mus spretus allele, e.g., will be present and the band
corresponding to Mus musculus (which carries the deletion) will be absent. On the
other hand, if the probe maps outside the deletion, then both the Mus spretus and the
Mus musculus bands will be present. The band corresponding to the Mus spretus allele

will always be present; therefore, the presence or absence of the Mus musculus band
indicates whether or not the probe is deleted (reviewed in Russell and Rinchik, 1987).
Similarly, any PCR amplification product that shows a polymorphism between Mus
musculus and Mus spretus can also be used for mapping, with the presence or absence

of the Mus musculus product determining whether or not the product maps within the
deletion (Metallinos et al., 1994).

Fine-structure mapping has been utilized to

molecularly characterize the genomic regions surrounding several of the deletion
complexes, including the albino (c) deletion complex on chromosome 7 (Johnson et al.,
1989; Rinchik et al., 1989; Holdener et al., 1995; Rikke et al., 1997), the p deletion
complex on chromosome 7 (Johnson et al., 1995; Dhar and Johnson, 1997; Culiat et al.,
1993; Culiat et al., 1994; Nicholls et al., 1993; Scrable et al., 1990; Stubbs et al., 1994;
Walkowicz et al., 1999; Wu et al., 2000), the brown (b) deletion complex on
chromosome 4 (Rinchik et al., 1994; Bell et al., 1995), the piebald (s) deletion complex
on chromosome 14 (Metallinos et al., 1994; O'Brien et al., 1996), the Brachyury (7)
deletion complex on chromosome 17 (You et al., 1997), and the interdigitated
Huntington disease (Hdh ), dipeptydylpeptidase VI (Dpp6), and y-aminobutyric acid
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receptor,

P-1subunit

(Gabrbl) deletion complexes on chromosome 5 (Schimenti et al.,

2000).
One advantage of using the deletion complexes for mapping, both genetic and
molecular, is that the resolution is much higher than that typically obtained using
traditional recombination mapping techniques (Rinchik and Russell, 1990; Bergstrom et

al., 1998; Schimenti et al., 2000). In addition, any probe or amplification product that
is polymorphic can be mapped relative to the deletion breakpoints.

This means that

entire genomic or cDNA clones, as well as anonymous clones and PCR products, can be
mapped, even if their genetic or biochemical function is unknown. The maps produced
by these types of analyses are dynamic; they continually evolve as the genes and
functional units in these regions become better understood.
Another important use of the deletion complexes and other chromosomal
rearrangements is in regional mutagenesis studies (Rinchik et al., 1990).

In fact,

deletions have been called the "critical genetic reagent" (Schimenti and Bucan, 1998)
that, along with the supermutagen ENU, has fueled the explosion of regional
mutagenesis experiments in the mouse in progress worldwide (Justice et al., 1999). By
mutagenizing a region of the genome corresponding to any of the deletion complexes, it
is possible to identify mutations through a hemizygous, two-generation breeding
scheme, rather than the three-generation screen that would be required to identify them
homozygously.

Furthermore, any recessive mutations detected in the hemizygous

breeding scheme presumed to map within the genomic location defined by the extent of
the deletion can be quickly fine-mapped using trans-complementation crosses to
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deletion carriers (Rinchik and Russell, 1990; Rinchik, 1991; Schimenti and Bucan,
1998; Schimenti et al., 2000).
Deletion complexes have also been utilized in other ways. For instance, the Krd
deletion has been used as a reagent in a sensitized screen for genes affecting kidney and
retinal function. This is possible because the paired box gene 2 (Pax2) maps within the
Krd deletion, and haploinsufficiency of Pax2 causes kidney and retinal abnormalities (Ji

et al., 1999). The deletion complexes have also be used to determine the biological
effect(s) of segmental haploidy on the specific regions of the genome covered by these
complexes (Schimenti et al., 2000). Mice carrying chromosomal deletions in the pdeletion complex of mouse chromosome 7 (Mmu7) have been used to study an obesity
phenotype that appears to be imprinted (Dhar et al., 2000), and mice carrying other
deletions are being used to dissect contiguous gene syndromes such as Wolf-Hirshhorn
syndrome (Schimenti et al., 2000) and DiGeorge syndrome (Lindsay et al., 1999).
Deletions and deletion complexes produced in the mouse are reagents of
unparalleled importance to mouse geneticists. The genetic and molecular analysis of
genomic regions corresponding to these deletions and deletion complexes has produced
a constantly evolving, high-resolution map of these regions. Recessive phenotypes and
mutations, as well as cDNA and genomic clones and other molecular probes and
markers (even anonymous markers), can be mapped relative to the deletion breakpoints
within the complex to produce a higher resolution map than can be produced through
traditional linkage analysis. Deletions and deletion complexes can be used to study
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genomic imprinting, to dissect the phenotypes associated with contiguous gene
syndromes, and as a genetic reagent in regional mutagenesis programs.

THE pink-eyed dilution (p) LOCUS
The pink-eyed dilution (p) locus of the mouse is an historically important region
of the mouse genome. The first report of genetic linkage in mammals was between p
and the albino (c), or tyrosinase (tyr) locus in the mouse (Haldane et al., 1915). In
addition, p is one of the seven genetic loci selected for use in the mouse SLT (Russell,
1951).
There have been over 100 mutations identified and reported at the p locus of
mouse chromosome 7 (Lyon et al., 1992; Brilliant et al., 1994; Johnson et al., 1995).
At least 45 of these p mutations are classified as chromosomal deletions of varying
sizes, and most of these deletions are homozygous-lethal (Russell et al., 1995). In the
mouse, the original p mutation, which is a recessive and hypomorphic allele (Rinchik et
al., 1993a), is of Mus musculus (Asian) origin, while the wild-type (P) allele is of Mus
domesticus origin (Brilliant et al., 1994). Mutations at the p locus are associated with

reduced pigmentation of both the eyes and skin, with a reduction in the quantity of
eumelanin (black-brown pigment) produced by the melanosomes as well as an
alteration of the size and shape of the melanosomes (Russell, 1949). The protein
encoded by the P gene is hydrophobic, with 12 putative transmembrane domains
(Rinchik et al., 1993a). It has a mass of 110 kDa and is localized to the membrane of
the melanosome (Rosemblat et al., 1994).
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In humans, the P locus maps to chromosome 15ql l.2-q12, and mutations at or

near this locus have been associated with several diseases, including Prader-Willi and
Angelman Syndromes and hypomelanosis of Ito (Gardner et al., 1992; Brilliant, 1992).
Mutations in the human P gene itself have been shown to cause tyrosinase-positive
oculocutaneous albinism type II (OCA2) (Ramsay et al., 1992; Rinchik et al., 1993a;
Lee et al., 1994). The human P protein contains 25 exons (the first of which is noncoding) and covers a genomic interval of between 250- and 600-kb. The protein is 838
amino acids long and, like the mouse protein, contains 12 putative transmembrane
domains and is localized to the melanosome membrane. The protein shows homology
to several prokaryotic transport proteins, including those from species such as
Escherichia coli, Staphylococcus aureus, and Mycobacterium leprae (Lee et al., 1995).

Therefore, although the exact function of the P protein has not been demonstrated, it is
hypothesized that this protein is likely involved in the transport of tyrosine or some
intermediate in the tyrosine metabolic pathway (Rinchik et al., 1993a).

THE pink-eyed dilution (p) DELETION COMPLEX
The pink-eyed dilution (p) deletion complex consists of a series of nested,
overlapping chromosomal deletions produced by the radiation mutagenesis programs at
the Oak Ridge National Laboratory and at the M.R.C. Radiobiology Unit at Harwell,
England.

The physical distance covered by the p-deletion complex is unknown;

however, it must span at least 6.6 cM of genetic distance, since p and Myodl are 5.5 cM
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apart and Gabrb3 and D7Cwr 15 are 1.1 cM apart, and all are contiguous within the
complex (Johnson et al., 1995) (Figure II-1, in the Appendix).
The p-deletion complex has been grossly molecularly characterized, and the
current genetic and physical map of the region includes gene loci, microsatellite
markers, and functional units (such as ruby-eye 2; ru2) (Russell, 1989; Johnson et al.,
1995; Stubbs et al., 1994; Dhar and Johnson, 1997; Wu et al., 2000; Scrable et al.,
1990; Walkowicz et al., 1999; Nicholls et al., 1993; Culiat et al., 1993; Culiat et al.,
1994). The proximal (nearest the centromere) region of the complex is homologous to
human chromosome llp14-p15 (Scrable et al., 1990; DeBry and Seldin, 1996), while
the distal (nearest the telomere) region of the complex, including P itself, is
homologous to human chromosome 15qll-q13 (Nicholls et al., 1993; DeBry and
Seldin, 1996). The p-deletion complex covers a genomic interval that spans from
lactate

dehydrogenase-C (Ldh3),

serum amyloid Al

(saal)

and myogenic

differentiation antigen 1 (Myodl) at the proximal end of the complex to y-aminobutyric
acid receptor, P-3 subunit (Gabrb3) and human papilloma virus E6-associated protein
(Hpve6a), later renamed ubiquitin-protein ligase E3a (Ube3a), at the distal end of the

complex (Russell and Rinchik, 1987; Scrable et al., 1990; Johnson et al., 1995). The
limits of the complex are defined by the proximal breakpoint of the most proximally
extending deletion, p 46DFioD, and the distal breakpoint of the most distally extending
deletion, p 30PUb (Russell, 1989; Johnson et al., 1995) (Figure II-I).
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N-ethyl-N-nitrosourea (ENU)
N-ethyl-N-nitrosourea (ENU) is the most effective mutagen identified in the
mouse, with a mutation rate 87 times higher than the spontaneous mutation rate and
over ten times the maximum mutation rate of a single dose of x-rays (Russell et al.,
1979b; Hitotsumachi et al., 1985). It is an alkylating agent that is both a toxin and a
carcinogen (reviewed in Justice et al., 2000). It can induce mutations in somatic and
germ cells in a variety of organisms; therefore, it can be used to induce somatic tumors
as well as germline mutations (Davis et al., 1999). ENU causes the highest mutation
rate in stem cell spermatogonia; however, it has been shown to cause mutations in
mature and maturing oocytes and post-spermatogonial stem cells at a lower rate
(Russell and Russell, 1992; Russell et al., 1979b). ENU is widely used in mutagenesis
experiments because of its high efficiency and its pronounced effects in spermatogonial
stem cells; mutagenized males can produce large numbers of offspring carrying these
mutations throughout their reproductive lifetime (Rinchik, 1991; Schimenti and Bucan,
1998).
ENU alkylates DNA through an SN 1 (unimolecular nucleophilic substitution)
reaction mechanism in which the ethyl group of ENU is transferred to one of several
nucleophilic oxygen or nitrogen atoms in any of the four bases of DNA. The sterically
altered (ethylated) base causes mispairing during DNA replication, resulting in a point
mutation in subsequent generations (reviewed in Noveroske et al., 2000).

A

compilation of sequence data from 62 END-induced alleles representing 24 genomic
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loci indicate that ENU modifies NT base pairs most frequently, with 82% of mutations
falling into this category (Justice et al., 1999).
The mutational spectrum of ENU analyzed to date includes missense mutations,
nonsense mutations, and splicing errors.

These mutations can be translated into

hypomorphic, antimorphic, hypermorphic, and amorphic proteins (Noveroske et al.,
2000).

ENU mutagenesis studies have produced multiple alleles at several loci,

including short ear (Bmp5) (Marker et al., 1997), myosin-VA (MyoVa) (Huang et al.,
1998a; Huang et al., 1998b), Juvenile development and fertility-2

(jdf2/Herc2)

(Walkowicz et al., 1999), and quaking (qk) (Cox et al., 1999). These allelic series are
invaluable reagents in the effort to elucidate the in vivo function of genes in a
mammalian system (Ji et al., 1999; Schimenti et al., 2000), enabling the determination
of structure-functional relationships in proteins caused by any number of point
mutations, and allowing the dissection of the biochemical pathways in which these
genes function.
In mouse spermatogonia, there is a threshold level below which ENU shows no

mutagenic effect, indicating that there are cellular mechanisms in place that can repair
the DNA damage done by ENU, provided that the damage is not too severe (Russell et
al., 1982b).

Therefore, fractionating a moderate dosage of ENU leads to a lower

mutation rate (Russell et al., 1982c). Conversely, it has been shown that weekly,
repeated doses of ENU increase the mutation rate and allow the animals to survive a
higher dosage that would, if administered in a single dose, be lethal (Hitotsumachi et
al., 1985). It has also been found that the effects of ENU can vary in the mouse from
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strain to strain; therefore, genetic background has an effect on ENU susceptibility
(Davis et al., 1999; Justice et al., 2000).
ENU is a potent point mutagen that primarily alters A/T base pairs in DNA. It is
currently the most effective mutagen tested in the mammalian germline, and its effects
are most pronounced in mouse spermatogonial stem cells.

One of the greatest

advantages of ENU is its ability to produce an allelic series at the locus of interest. Its
high mutation efficiency, coupled with its ability to produce allelic series, make ENU
the mutagen of choice for most mutagenesis experiments.

REGIONAL MUTAGENESIS

There are several regions of the mouse genome where deletions have been
utilized as genetic reagents for regional mutagenesis studies.

These studies involve

using ENU to mutagenize a region of the genome that is covered by a deletion, to
effectively "saturate" the genomic region with point mutations induced by ENU and
recover these mutations hemizygously using long deletions (reviewed in Rinchik and
Russell, 1990). It has been suggested that a true "saturation mutagenesis" is probably
not possible, however, due to the variable mutability of different genetic loci (Rinchik
and Carpenter, 1999). The advantages to this method are numerous. ENU is the most
potent mutagen in mouse spermatogonial cells, so it is ideal for mutagenizing male mice
with high efficiency.

It produces primarily point mutations, so many different

mutations are possible for each gene; therefore, it is possible to produce allelic series,
which are useful in determining the functions of the genes within the context of the
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animal. Finally, the use of deletions allows the mutations to be recovered hemizygously
in only two generations, rather than the three generations that would be required to
recover them homozygously (Rinchik, 1991).

REGIONAL MUTAGENESIS EFFORTS AT ORNL
There have been three major regional mutagenesis projects performed at ORNL.

In each case, the mutagenesis projects involve the use of ENU as the mutagen and
deletions produced from the radiation mutagenesis experiments at ORNL to recover the
mutations in hemizygotes.

Since the deletions are opposite an easily identifiable

morphological marker, the test and carrier classes are conveniently "marked" by their
morphological features, such as coat and eye color (Rinchik, 2000).

The ORNL

mutagenesis efforts have utilized five deletions at three loci: one deletion from the
albino (c; Tyr) deletion complex (Rinchik et al., 1990; Rinchik and Carpenter, 1993 and
1999; Rinchik et al., 1993b), two deletions from the brown (b; Tyrpl) deletion complex
(Rinchik, 2000; Dabney Johnson, personal communication), and two deletions from the

pink-eyed dilution (p) deletion complex (Rinchik et al., 1995; Rinchik, 2000).

REGIONAL MUTAGENESIS WORK IN THE p-DELETION COMPLEX
The ORNL mutagenesis work in the p-deletion complex has used two different
deletions, p 46DFiOD and p3°PUb. Although these deletions are overlapping and both delete
the p gene, the proximal breakpoint of p 46DFiOD and the distal breakpoint of p 30PUb define
the proximal and distal limits, respectively, of the p-deletion complex (Figure II-1).
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Both of these deletions are homozygous-lethal (Russell et al., 1995), and the p46DFiOD
deletion, which is cytologenetically visible (Rinchik and Russell, 1990), deletes both p
and ru2, another coat and eye color mutation located approximately 3 cM proximal top
(Russell, 1989). The p3°PUb
deletion deletes p and the y3, a 5, and

p3 subunits

of the y-

aminobutyric acid receptor (Gabrg3, Gabra5, and Gabrb3) as well as the ubiquitinprotein ligase E3a (Ube3a) (Johnson et al., 1995).

MUTAGENESIS USING THEp 46DFiOD DELETION

The mutagenesis protocol utilized for this project involves the p 46DFiOD deletion,
which has two morphological markers, p and ru2.

The mutagenized males are

homozygous ru2 p I ru2 p; therefore, the mutagenized chromosome carries the both the
original p mutation and ru2, another recessive mutation that produces deep ruby-colored
eyes and a somewhat diluted gray-brown coat (Silvers, 1979). These males are then
crossed to females that are homozygous wild-type (+/+) to produce wild-type G 1
offspring (unless a dominant mutation is induced). The G 1 offspring are then mated to
animals that carry the p 46DFiOD deletion (represented by~) opposite ru2. This cross can
produce three classes of animals: pink-eyed, ru2 animals (ru2 p I~), which would be
the test class; ru2 animals (ru2 p I ru2 +, with + representing the wild-type allele, P),
which are the carrier class; and wild-type (either ru2 + I + + or + + I ~). Induced
recessive mutations are detected in the pink-eyed, ru2 test class of animals, and
deleterious or lethal mutations are recoverable in the ru2 carrier class of animals
(Rinchik, et al., 1995) (Figure II-2).
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CHAPTER ill
MAPPING THE psrt PHENOTYPE

There are two stocks of psrt animals at ORNL, 723SJ and 1060SJ,
independently generated in the p-region mutagenesis program. These mutations map
between the p and ru2 loci on Mmu 7 (Figure lli-1). They exhibit identical phenotypes,
which were originally called "small nervous," and they are non-complementing. Transcomplementation data indicate that both of these mutations map to the same p-deletion
interval (E. Rinchik and D. Carpenter, unpublished data), suggesting that these
mutations are allelic.
Trans-complementation data show that only four of the p-deletions do not
complement these two psrt phenotypes: p 46DFioD, p 47Dm, p 3RD3ooH,and p 2MNURJ_ All
other p-deletions tested complement the phenotype (E. Rinchik and D. Carpenter,
unpublished data), thereby narrowing down the minimal genomic region known to
contain the mutant phenotype to a region of Mmu 7 bordered proximally by the
proximal breakpoint of p 2MNURJ and bordered distally by the proximal breakpoints of
p 8°K and p 8R250M, which cannot be resolved at this time (Figure lli-1 ). The p3RD 3ooH

deletion does not complement the psrt phenotype; however, at the beginning of this
project, its breakpoints had not been well defined and were better characterized in the
course of this study.
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CHAPTER IV
PHYSICAL MAPPING IN THE psrt REGION OF MOUSE CHROMOSOME 7

ABSTRACT
A physical map was produced in order to positionally clone the gene responsible
for psrt, a profound seizure and runting phenotype that maps into the p-deletion
complex of Mmu 7. The minimal genomic region determined to contain psrt has been
further defined by molecularly mapping the breakpoints of the p 3RDJOOH deletion. Two
bacterial artificial chromosome (BAC) libraries were screened using molecular markers
from the region, and the BACs identified in the screen were further characterized to
determine their size and to generate sequence tagged sites {STSs) from their terminal, as
well as internal, sequences.

BAC STSs and other molecular markers were mapped

using deletion panel blots and Southern blots of restriction digested BAC DNAs, and
data produced were used to assemble and order the physical map. A physical map of a
portion of the psrt minimal genomic region has been produced, and BAC clones from
this map were utilized (see Chapter V) to identify transcriptional units in an attempt to
identify the gene responsible for the psrt phenotype.

INTRODUCTION
1. Positional Cloning
This project used positional cloning to identify the gene responsible for the psrt
phenotype in the mouse. Positional cloning is a technique that was first utilized in the
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1980s to clone the human gene responsible for chronic granulomatous disease (RoyerPokora et al., 1986). Since that time, positional cloning has been used to clone a
number of genes in a variety of organisms, including the human genes responsible for
Duchenne muscular dystrophy, cystic fibrosis, type 1 neurofibromatosis, fragile X
syndrome, and numerous other diseases (Collins, 1992; Talbot and Schier, 1999;
Boehm, 1998). The aim of positional cloning is to isolate and clone a gene based solely
on its chromosomal position in the absence of information about the nature of function
of either the gene or its protein product (Collins, 1992).
Positional cloning projects have three basic steps: identifying and mapping
linked markers, constructing a physical map of the genomic interval determined to
contain the gene, and searching for genes within this region (Stubbs, 1992; Collins,
1992). In the first step, identifying and mapping linked markers, pedigrees in which the
gene of interest is segregating are collected and analyzed (Collins, 1992). This can be
done either in humans or in model organisms, such as the mouse, and entails analyzing
polymorphic markers from the region to determine evidence of linkage between the
mutant phenotype and any of these markers (Collins, 1992; Boehm, 1998).

By

determining which markers are genetically linked to the mutation, it is possible to
establish the limits for the region of the genome containing the mutation. The second
step is the construction of a physical map, consisting of a contiguous, overlapping series
of genomic clones covering the region of the genome identified in step one (Stubbs,
1992). The third step in a positional cloning strategy is identifying transcriptional units
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within the genomic interval of interest and analyzing each of these for suitablilty as a
candidate for the mutant phenotype (Collins, 1992).

2. Positional Candidate Approach
The positional candidate approach, which is a separate but related strategy, has
been successfully utilized to clone several genes, including those responsible for
amyotrophic lateral sclerosis (Lou Gehrig's disease), Waardenburg syndrome, and
Charcot-Marie-Tooth disease (Ballabio, 1993). The positional candidate approach can
be used when some biochemical or functional information is known about the disease.
The disease phenotype is mapped in a similar manner to a positional cloning strategy;
however, it is not necessary to go through the laborious process of producing a physical
map of the region. Once the disease has been mapped, then the available databases are
searched for genes and expressed sequence tags (ESTs) mapping into the region, and
candidate genes are proposed by evaluating likely functional suitability and by looking
for mutations in their transcripts (Ballabio, 1993).

3. Mapping Markers in the psrt Region of Mouse Chromosome 7
The first step in any positional cloning strategy is to identify and map markers
linked to the mutation to define the limits of the minimal genomic region containing the
mutation. Any markers identified and mapped in this step can be used to "anchor" the
physical map (Stubbs, 1992; Collins, 1992). In the mouse, this is readily accomplished
through the use of polymorphic markers, such as microsatellites (Boehm, 1998).
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A trans-complementation

analysis of the psrt mutation has narrowed down the

minimal genomic region known to contain the mutation to a region of Mmu 7 bordered
proximally by the proximal breakpoint of p 2MNURf and bordered distally by the proximal
breakpoints of p 8°K and p 8R250M, which cannot be resolved at this time (Figure ill-1).
The p 3RDJOOH deletion does not complement the psrt phenotype; however, its breakpoints
have not been well defined. An earlier molecular analysis of 36 mutations at the p locus
determined that the p 3RDJOOHdeletes growth arrest 2 ( Gas2), D7H 15F3 7S1, and p, three
molecular markers, as well as l7Rll, a phenotype-defined marker that maps between

Gas2 and D7Hl 5F37S1.

The proximal breakpoint of the p 3RDJOOH lies in the genomic

region between Gas2 and ru2, and the distal breakpoint lies between p and Gabrg3
(Johnson et al., 1995). A subsequent molecular analysis of the p-deletion complex
mapped fourteen microsatellite markers relative to the previously defined deletion
breakpoints (Dhar and Johnson, 1997). The microsatellite study, however, included
only 23 of the p-region deletions; so not all of the deletions utilized for the first study
were included in the second study. Since the p 3RDJOOH was one of the p-deletions that
did not complement the psrt phenotype and was not included in the microsatellite study,
further defining the proximal breakpoint of this deletion may serve to narrow down the
minimal genomic region known to contain the psrt mutation.

4. Constructing the Physical Map of the psrt Region
Constructing a physical map of the minimal genomi~ interval determined to
contain the gene is the second step in the process of positionally cloning the gene
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responsible for the psrt phenotype. Generating and fine-mapping new markers in the
region relative to the deletion breakpoints and to the BAC clones in the region will
allow the clones to be assembled into a contig covering the region. The clones from the
contig will then be analyzed to identify transcriptional units, and an expression analysis
of the psrt and control animals will be used to assess the candidacy of any genes
identified in the process.

MATERIALS AND METHODS
1. Deletion Panel Mapping of Microsatellites
D7Mit230

and D7Mit312, two microsatellite markers that show size

polymorphism between Mus musculus and Mus spretus, were mapped by PCR using
genomic DNAs from interspecific hybrid (Mus musculus X Mus spretus)F 1 carriers of
various p deletions in which a different Mus musculus p-region deletion chromosome
was balanced opposite a Mus spretus chromosome (Johnson et al., 1995; Dhar and
Johnson, 1997).

F 1 interspecific hybrids were generated as described previously

(Johnson et al., 1989).
Oligonucleotide pnmers for the microsatellite markers were obtained from
Research Genetics Inc. (Huntsville, AL), and PCRs were performed using a 20 µL total
reaction volume containing 10-50 ng of template DNA, 2 Units of Taq DNA
Polymerase (Gibco BRL Life Technologies, Inc.; Gaithersburg, MD), 0.6 µM each
primer (forward and reverse), and 14 µL of PCR mix to give a final concentration of 1.5
mM MgCli and 1X PCR buffer. Reactions were carried out in 0.2 mL PCR tubes using
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a PTC-100 thermocycler (MJ Research, Waltham, MA) and the following program:
initial denaturation at 94°C for 5 minutes followed by 30 cycles of denaturation at 94°C
for 45 seconds, annealing at 45°C for 45 seconds, and extension at 72°C for 150
seconds, then a final five minute extension step at 72°C. PCR products were analyzed
on 3% NuSieve GTG agarose gels (FMC Bioproducts, Rockland, ME) made with lX
TAE (0.04 M Tris-acetate, 0.001 M EDTA) and visualized under UV light after staining
with ethidium bromide.

2. Defining the Breakpoints of p 3RD3ooH

3ooHwere defined by PCR amplification of eight
The breakpoints of p3RD
microsatellite markers using genomic DNA from interspecific hybrid (Mus musculus X

3oondeletion. The eight microsatellite markers used
Mus spretus )F 1 carriers of the p3RD
were D7Mit26, D7Mit69, D7Mit70, D7Mit84, D7Mit145, D7Mit160, D7Mit193, and
D7Mit230. Reactions were performed, and PCR products were analyzed, as described

above.

3. BAC Library Screenings
The Genome Systems, Inc. (St. Louis, MO) "Down to the well" Mouse (strain
129SV) ES BAC DNA pools were screened by PCR using primers for D7Mit145,
D7Mit193, D7Mit194, and D7Mit230. The reactions were performed using 3 µL of the

BAC superpool DNA in a 20 µL total reaction volume, using the same reagents and
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thermocycling program as described above, annealing at 45°C (or 48°C for D7Mit145)
for 35 cycles. PCR products were analyzed as described above.
The Genome Systems, Inc. (St. Louis, MO) BAC Mouse Library (Release II)
high density filters were also screened by hybridization using RT 591/592, a 287 bp
RT-PCR product from the mouse Prmt3 cDNA. The generation and analysis of this
RT-PCR product is described in detail in Chapter VI (Sequence and Expression
Analyses of Candidate Genes). Standard hybridization conditions were utilized, and
blots were washed three times, with a final 20 minute wash at 65°C in 0.1 X SSCP.
BACs screened by hybridization were confirmed by PCR, using primer pair ORN
591/592, annealing at 50°C for 35 cycles. BACs were grown in LB medium plus
chloramphenicol (12.5 µg/mL) and BAC DNA was isolated using either the Promega
Wizard® Plus Minipreps DNA Purification System (Promega Corporation, Madison,
WI) or the Qiagen Plasmid Midi Kit (Qiagen Inc., Valencia, CA) according to the
manufacturer's instructions.

4. Determining the Size ofBAC Inserts
BACs were grown and the DNA was isolated as described above. BAC DNAs
were digested overnight at 37°C with Natl (Gibco BRL Life Technologies, Rockville,
MD) using the following reaction cocktail: 10µL of miniprep or midiprep DNA, 2.5 µL
of 10 X React3 and 2 µL (15 units/µL) Natl (Gibco BRL Life Technologies, Rockville,
MD), and 10.5 µL of sterile water. Digested DNAs were loaded on a 1% agarose gel
which was run in 0.5X TBE at 14°C. Electrophoresis was performed in a BioRad Chef
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Mapper pulsed field gel electrophoresis (PFGE) apparatus using the autoalgorithm
function programmed to separate fragments ranging from 50-kb to 500-kb. The gel was
stained with ethidium bromide and visualized under UV light. The size of the inserts
was determined by comparison to low-range and mid-range PFGE markers (New
England Biolabs, Beverly, MA).

5. BAC Endcloning and STS Generation
STSs were generated from the terminal sequences of the BACs usmg a
modification of the ligation linker PCR method (Riley et al., 1990; Mueller and Wold,
1989). Briefly, the BAC is digested with several different restriction enzymes, an oligo
linker is ligated to the fragments, and PCR is performed on the digested fragments using
primers for the oligo linker and either the SP6 or T7 promoter sequences, which are in
the BAC vector near the cloning site (Shizuya et al., 1992; Kim et al., 1996). STSs
were also generated from internal sequences by single primer PCR using primers for the
Bl and B2 repeat sequences in the mouse (Kim et al., 1997a).
The PCR products obtained were cloned using the pGEMT-Easy II cloning kit
(Promega Corporation, Madison, WI) and analyzed by fluorescent sequencing with the
Big Dye Terminator Kit (PE Biosystems, Foster City, CA). The products were run on
an

ABI377

DNA

sequencer

and

the

sequence

analyzed

using

BLAST

(http://www.ncbi.nlm.nih.gov/BLAST/) to verify the identity of the cloned products.
STS clones were verified by mapping back to the p-region of Mmu 7 using deletion
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panel Southern blots and standard hybridization protocols (Johnson et al., 1995; Dhar
and Johnson, 1997).

6. Placing STSs on the Physical Map
STSs were placed on the physical map in one of two ways: by PCR or by
hybridization.

Nine microsatellite markers (D7Mit26, D7Mit69, D7Mit70, D7Mit84,

D7Mit145, D7Mit160, D7Mit193, D7Mit229 and D7Mit230) and one EST (RT
591/592) were amplified by PCR using BAC miniprep DNAs and conditions described
above (D7Mit229 was annealed at 40°C for 35 cycles). D7Mit229 was used with the
BAC DNAs, but not for mapping with the deletion panels, because it is not polymorphic
between Mus musculus and Mus spretus. BACs positive for the STS will show an
amplification product of the expected size.
Other STSs were placed on the physical map by hybridizing to Southern blots of
BAC DNAs digested with EcoRV. BACs positive for the probe show a hybridization
band of the appropriate size in the autoradiograph of the washed blot. Seven STSs were
placed on the physical map by hybridization, including four BAC end clones
(B36n 10/EcoRV /SP6,

B36n10/EcoRV/T7,

B 179d 14/EcoRV/SP6,

and

Bl 79d14/EcoRV/T7), and two RT-PCR products from the Prmt3 gene, RT 595/596 and
RT 591/592, which was also mapped by PCR (Table IV-1, in the Appendix).
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7. Deletion Panel Mapping of Probes
STS

clones

and other probes

showing

a restriction

fragment

length

polymorphism (RFLP) between Mus Musculus and Mus spretus were verified by
mapping to the p-deletion complex by hybridization using deletion panel Southern blots
and standard hybridization protocols (Johnson et al., 1995; Dhar and Johnson, 1997).
Probes were isolated on 1% LMP (low melt point) Agarose (Gibco BRL, Rockville,
MD) then melted and random prime labeled with [a-32P]dCTP.

Hybridizations were

performed at 42°C overnight, and blots were washed three times: 20 minutes at room
temperature in 2X SSCP with 0.1 % SOS, followed by 20 minutes at 65°C in 2X SSCP
and 20 minutes at 65°C in 0.lX SSCP.
hybridization to deletion panel blots:

The following probes were mapped by

B36n10/B2A, B4514/Pvu/T7, Bl 79dl4/B1B,

Bl 79d14/EcoRV/SP6, Bl 79dl4/EcoRV/T7, RT 591/592.

RESULTS
1. Deletion Panel Mapping of Microsatellites
In order to better define the region of the genome surrounding the psrt locus,

two microsatellite markers were mapped.

A PCR analysis of D7Mit230 using the

deletion panel DNAs shows that the Mus musculus band is absent for p 46DFiOD, p 47DTD,

p 2MNURf, and p 3RD3 ooH, while it is present in p 8°K and p 8RisoM_ The absence of the Mus
musculus band indicates that the marker is deleted; therefore, the marker must lie
between the proximal breakpoints of p2MNURJ and p 3RDJOOH (which are unresolved at this
time) andp 8 °K andp 8RlJOM (which are also unresolved). A similar analysis of D7Mit312
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shows that the Mus musculus band is present for all six deletion DNAs, which means
that the marker is not contained within the deleted region for any of the six deletions
tested. Therefore, D7Mit312 must map outside the p-deletion complex (Figure IV-2).

2. Defining the Breakpoints of p 3RD3ooH
PCR analysis of eight microsatellite markers in the p-deletion complex has
further defined the breakpoints of p 3RDJOOH_ Three of the microsatellite markers tested
were deleted in p 3RDJOOH: D7Mit193, D7Mit230, and D7Mit145.

Five of the

microsatellite markers were not deleted: D7Mit26, D7Mit69, D7Mit70, D7Mit84, and
D7Mitl 60. This means that the proximal breakpoint of p3RDJOOH is between D7Mit26
and D7Mit69 (which cannot be resolved at this time) and D7Mit193 and D7Mit230
(which also cannot be resolved). Previously, the proximal breakpoint of this deletion
was known to be somewhere between Ldh3 and Gas2 (Johnson et al., 1995). The distal
breakpoint of the p 3RDJOOH deletion is between D7Cwrl 5 and D7Mit84.

Previous

mapping studies indicate that the p 3RDJOOHdeletion encompasses the D7HJ 5F37S1 locus
(Johnson et al., 1995) and the D7Mit70 locus maps proximal to D7H15F37S1, between
D7HJ 5F37S1 and D7Mit196 (Wu et al., 2000). These data indicate that D7Mit70 is not
deleted in p 3RD300H, meaning that p 3RD3ooH is a "skipper," which is a noncontiguous
deletion most likely involving some sort of complex rearrangement (Johnson et al.,
1995) (Figure IV-3).
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3. BAC Library Screenings
A total of eleven BACs from the Genome Systems, Inc. (St. Louis, MO) "Down
to the well" Mouse ES BAC DNA pools were screened by PCR using primers for four
different microsatellite markers mapping near the psrt region. There were four BACs
selected using microsatellites mapping within the psrt minimal interval: three positive
for D7Mit193 (B36nl0, B4514, and B179dl4) and one positive for D7Mit230 (B21 li3).
In addition, D7Mit145, the microsatellite marker mapping in the distally adjacent
deletion interval, was used to identify two BACs (B207pl 7 and B212f2). D7Mit194,
which maps in the most proximal deletion interval and may be useful in cloning ru2,
was used to select five BACs (B47g18, B47g22, B142k10, B142k22, and Bl 78n12).
There were also twelve BACs from the Genome Systems, Inc. (St. Louis, MO)
BAC Mouse Library (Release II) high density filters that were identified by
hybridization using RT 591/592, a 287 bp RT-PCR product from the mouse Prmt3
cDNA, as the probe. They are: B242g12, B279114, B288k21, B315k22, B329d6,
B333e23, B34416, B354kl 1, B372t7, B382013, B434g10, and B462a15. These BACs
were confirmed by PCR using four different sets of primers: RT 591/592, which was
used to amplify the RT-PCR product that was used to screen the library; D7Mit193,
which maps in the psrt minimal interval; ORN 609/610, which corresponds to the T7
end of B4514; and ORN 607/608, which corresponds to the terminal sequence of
B 179d 14. The BA Cs were then subdivided into categories based on the results of the
PCRs (Table IV-4).
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4. Deletion Panel Mapping of STSs
Deletion panel Southern blots were used to map probes showing an RFLP
between Mus musculus and Mus spretus.

Seven probes were mapped this way,

including three BAC end clones (B36nl0/EcoRV/SP6, Bl 79dl4/EcoRV/SP6, and
Bl 79dl4/EcoRV/T7), and two STSs derived from single-primer PCR (B36nl0/B2A
and B 179d14/B1B). In every instance, the Mus mus cu/us bands are present in p 8°K and
PBR250M

and absent inp46DFiOD,p47DTD,p3RD300H

are deleted in in p46DFiOD,

p47DTD, p3RD300H

andp2MNURf,

which means that the probes

and p2MNUR~ but not in in PBOK and PBR250M_

Therefore, these seven probes must map proximal to the

p 8°K

and p 8R250M proximal

breakpoints and distal to the p 3RD300H and p 2MNURf proximal breakpoints, which is the
genomic region identified as the psrt minimal deletion interval (Figure IV-5).
There were two STSs that appear to contain repetitive sequences because they
showed smears rather than distinct hybridization bands. Therefore, these STSs could
not be used as probes for hybridization and no mapping results could be obtained for
them. They are: B4514/Rsa/SP6and B21 li3/EcoRV/T7a.

5. BAC Insert Sizes
PFGE was used to determine the insert size of six of the BACs used to produce
the physical map. The six BACs and their calculated insert sizes are: B36n10 (120-kb),
B4514 (120-kb), Bl 79dl4 (150-kb), B207pl 7 (280-kb), B21 li3 (125-kb), B212f2 (190kb). Four of the BACs have a single internal Natl restriction site (B36nl 0, B4514,
Bl 79d14, and B21 li3), one BAC has two sites (B207pl 7), and one has zero (B212f2)
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(Table IV-6).

All of the BACs whose insert size was determined were from the

Genome Systems, Inc. (St. Louis, MO) "Down to the well" Mouse ES BAC DNA
pools.

6. Assembly of the Physical Map
The physical map was assembled by identifying the markers present on each of
the clones, checking for overlap of the markers on the BACs, then ordering them into a
contig. The map consists of thirteen BACs, seven from the "Down to the well" Mouse
ES BAC DNA pools, and six from the BAC Mouse Library (Release II) high density
filters. The insert sizes of the BACs from the latter were not determined. Two sets of
BACs were determined to contain the same markers: B315k22, B372f7 and B382o13
all contain RT 591/592 and ORN 607/608; and B242g12, B288k21, B34416, and
B462a15 all contain D7Mit193, ORN 609/610, and ORN 607/608.

To minimize

redundancies, only one of the BACs from each of these two groups is included in the
map (Figure IV-7).

DISCUSSION
Fine-mapping the endpoints of the p 3RDJOOH deletion places the proximal
breakpoint between the same two sets of microsatellite markers as the p 2MNURf deletion.
Since both p 3RD3ooH and p 2MNURJ fail to complement the psrt phenotype, their proximal
endpoints (which cannot be resolved at this time) must define the proximal limit of the
minimal genomic interval determined to contain the psrt mutations. The distal limit of
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the interval is defined by the proximal breakpoints of p 8°K and p 8R250M. Therefore, the
physical map should cover the entire minimal region, from the proximal breakpoints of
p3RDJOOH

and p 2MNURf to the proximal breakpoints of p 8°K and p 8R250M, to ensure that the

psrt transcriptional unit is included.

The current physical map of the region does not completely span the psrt
minimal region because there is not uninterrupted coverage from one end of the
minimal region to the other (Figure IV-7). The physical size of the region is unknown;
therefore, it is impossible to know how complete the map is at this time. The map does,
however, contiguously span an area within the psrt minimal genomic region that
includes three microsatellite markers and ten molecular probes (Figure IV-7). The
physical map, while not complete, provides a number of BAC clones that can be
analyzed to identify transcriptional units in the region that may be responsible for the
psrt phenotype.
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CHAPTERV
SEQUENCE ANALYSIS OF BAC B179dl4 AND IDENTIFICATION
OF CANDIDATE GENES

ABSTRACT
Sequence analysis of BAC B 179d14 has identified two candidate genes for the

psrt phenotype:

Tat-interacting protein (30 kD) (Tip30) and protein arginine N-

methyltransferase (Prmt3). A third candidate gene, glycine transporter type 2 (G/yt2),
was identified because of its location in the human genomic region of homology and its
function in neurotransmission.

The sequence of BAC B 179d 14 was used to determine

the structure of a 150-kb genomic interval containing the mouse Tip30/Cc3 and Prmt3
genes.

INTRODUCTION
The process of identifying candidate genes is an important part of any positional
cloning or positional candidate strategy. These two strategies are related and can be
complementary. The positional cloning approach differs from the positional candidate
approach in that positional cloning involves the laborious step of producing and
assembling a physical map of the genomic region determined to contain the mutation,
followed by a search for transcriptional units within the region (Collins, 1992). The
positional candidate approach, on the other hand, can be utilized when some
biochemical or functional information is known about the disease.

Transcriptional
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units are identified through searching the available databases for genes and ESTs
mapping into the region (Ballabio, 1993). Once candidate genes have been identified
using either approach, expression and sequence analyses are required to evaluate the
validity of their candidacy by determining if mutations exist in the transcripts (Collins,
1992; Ballabio, 1993). Since some information is known about the psrt phenotype, it is
possible to utilize both the positional cloning and positional candidate approaches to
identify and clone the gene responsible for psrt.
Once the physical map is assembled, it is necessary to isolate and identify
transcriptional units in the genomic (BAC) clones that compose the physical map.
There are numerous techniques available for this purpose (Parimoo et al., 1995). They
range from splicing signal-based methods such as exon trapping (Duyk et al., 1990;
Krizman and Berget, 1993) and exon amplification (Buckler et al., 1991; Church et al.,
1994) to methods relying on the identification of either CpG islands or phylogenetically
conserved sequences (Parimoo et al., 1995) to cDNA selection (Parimoo et al., 1991)
and direct selection (Lovett et al., 1991) to sequence and computational-based methods
utilizing DNA sequencing (Claverie, 1994) and analysis of the sequence utilizing
programs such as the gene recognition and analysis internet link (GRAIL) (Uberbacher
and Mural, 1991).
The method chosen for this project was random shotgun DNA sequencing
followed by computer analysis of the sequence to detect transcriptional units.
Sequencing was done by randomly fragmenting the original BAC clone and subcloning
the fragments into a vector that is easily sequenced.

A comparison of the sequencing
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results will identify overlap, which can be used to assemble the sequences into contigs.
Contigs are screened for repetitive elements and the sequence is analyzed for
transcriptional units (Claverie, 1994).
This project was accomplished using a combination of the positional cloning
strategy and the positional candidate approach.

A search of the databases occurred

concomitantly with the development and assembly of the physical map in an effort to
identify the gene responsible for the psrt phenotype.

MATERIALS AND METHODS
1. Selecting a BAC for Sequencing
The BAC clone chosen for sequencing was B 179d 14, from the Genome
Systems, Inc. (St. Louis, MO) "Down to the well" Mouse ES BAC DNA pools.
Bl 79d14 was one of the first group of BACs screened, and was selected using

D7Mit193, which maps in the same deletion interval as the psrt phenotype. Its size,
determined by PFGE, is approximately 150-kb. There are seven STSs contained on
Bl 79d14 that have been fine-mapped back to the psrt minimal region, and three other
STSs that could not be mapped to the deletions (because they do not show an RFLP
between Mus muscu/us and Mus spretus) but were mapped to BAC clones in the region.
This means that Bl 79dl4 is most likely not chimeric, because it contains ten molecular
markers within 150-kb that map to the same deletion interval.
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2. BAC DNA Purification, Subcloning, and Sequencing
BAC DNA was isolated using the Qiagen Mega Prep Kit (Qiagen Inc., Valencia,
CA)

according

to the manufacturer's

instructions,

recommended volume for solutions Pl, P2, and P3.

except

using

double

the

The BAC DNA was further

purified through two cycles of CsCl gradient centrifugation (Sambrook et al., 1989).
Approximately 20% of the DNA was then sheared using a Gene Machine Hydroshear
on a setting of eight, and the sheared DNA was treated with T4 Polymerase to make
blunt ends.

The sheared, blunt ended DNA was ligated into the pBSK- vector

(Stratagene Inc., La Jolla, CA) that had been EcoRV digested and phosphatased. The
ligated DNA was electroporated into E. coli DH5a

cells (Gibco BRL Life

Technologies, Rockville, MD) and putative transformants were selected on LB plus
Ampicillin (100 µg/mL) plates.
Plasmid DNA from the subclones was isolated on a Qiagen BioRobot 9600
using the QIAprep 96 Turbo BioRobot Kit (Qiagen Inc., Valencia, CA). The templates
were then sequenced using either the Dye Primer or Big Dye Terminator Kits (PE
Biosystems, Foster City, CA) and the products run on an ABI377 DNA sequencer.

3. Analysis of Sequence Data
Sequence data were processed and assembled using the Phred, Phrap, and
Consed package of progams on an SGI 02 workstation. Approximately 2,440 subclones
were sequenced to produce approximately 8X coverage.

Repeat sequences were

identified using RepeatMasker (University of Washington, Seattle, WA). Additional
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analyses were performed using either the Wisconsin Package of programs, Version 10
(Genetics Computer Group, Madison WD, the Genome Channel software (ORNL, Oak
Ridge,

TN;

http://www.genome.ornl.gov)

or

the

NCI

BLAST

program

(http://www.ncbi.nlm.nih.gov/BLAST).

4. Database Search for Positional Candidates
The

human

genome

sequencing

database

at the National

Center for

Biotechnology Information (NCBD was searched for candidate genes mapping within
the (human) llp14-p15
Mmu

7.

The

genomic interval, which is homologous to the psrt region of
database

1s

(http://www.ncbi.nlm.nih.gov/genome/seq).

located

at

the

NCBI

website

Genes mapping in the 1lp14-p15 interval

were accessed by following the "human genome resources" link, selecting chromosome
11, and scrolling to the 11p 14-p 15 interval and zooming in or out, as necessary. There
are links for every gene listed which will open a new page with information and links
on the gene symbol, locus information, map information, NCBI reference sequence,
GenBank sequences, and annotations.

RESULTS
1. Candidate Gene Identification
There were two genes identified from a BLAST search of the repeat-masked
sequence data from BAC Bl 79dl4: the human Tat-interacting protein (30kD), TIP30
(Genbank accession # NM_006410), and the Rattus norvegicus protein arginine N-
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methyltransferase 3, Prmt3 (Genbank accession # AF059530). A search of the human
genome sequencing database identified several genes in the human 11p 14-p15 interval.
Although no known human disease genes were found to map within this interval, the
glycine transporter type 2 (GLYT2) gene (Genbank accession # AF085412) was
identified as a positional candidate because of its function in neurotransmission.

2. Structure of the Insert ofBAC Bl 79dl4
The insert of BAC Bl 79d14 is approximately 150-kb in length, as determined
by both PFGE and sequencing data. It contains Tip30/Cc3 and Prmt3, both of which
are transcribed in the same direction, separated by approximately 5-kb of genomic
sequence. The Tip30/Cc3 gene is approximately 15-kb in length, while the Prmt3 gene
is approximately 85-kb. There is a single Natl restriction site in the CpG island near the
5' end of Prmt3, and D7Mitl93 is located just 5' of Tip30/Cc3. There is approximately
25-kb of sequence 5' of Tip30/Cc3, and approximately 20-kb of sequence 3' of Prmt3
(Figure V-1).

3. Genomic Structure of the Tip30/Cc3 Gene
The murine Tip30/Cc3 gene is composed of five exons spanning approximately
15-kb of genomic sequence. The exons range in size from 62 to over 200 bp in size,
and the introns range from 660 bp to approximately 8-kb (Table V-2).
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4. Genomic Structure of the Prmt3 Gene
The murine Prmt3 gene is composed of 16 exons spanning approximately 85-kb
of genomic sequence. The exons range from 51 hp to 188 hp in size, and the introns
range from 80 hp to over 19-kb (Table V-3).

DISCUSSION
BAC B 179d 14 was chosen for sequencing for several reasons. It was one of the
first BA Cs screened; as such, it has been well characterized. Both ends of the BAC, as
well as an internal STS, have been cloned and fine-mapped to the p-deletion complex.
It is a fairly large clone, with an insert size of approximately 150-kb. And it is most

likely not chimeric, because it contains nine molecular markers within its 150-kb insert
that map to the same deletion interval.
The genomic sequence of Tip30/Cd has not been published; however, a similar
cDNA, named Td (for truncated Cd), has been described (Genbank accession #
AF092095). The TC3 and CC3 proteins share a similar N-terminal domain; however,
TC3 has a unique, shorter C-terminus. While Cc3 is a tumor suppressor that functions
through activation of the apoptotic pathway, Tc3 is a tumor promoter that strongly
inhibits apoptosis. It has been postulated that Cd and Td are alternatively spliced
transcripts from the same genomic locus (Whitman et al., 2000). Data from this project,
however, dispute this claim.

A full 110-kb of genomic sequence downstream of

Tip30/Cd has been sequenced in this BAC, and the unique portion of the Td transcript
is not present in this sequence in mouse. This 110-kb of sequence includes the 5-kb
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intergenic space between Tip30/Cc3 and Prmt3, the 85-kb that comprises the Prmt3
gene, and 20-kb of sequence downstream of Prmt3; therefore, it is unlikely that
Tip30/Cc3 and Tc3 are alternatively spliced transcripts arising from the same genomic

locus.
Sequence analysis of BAC B 179d14 has provided two candidate genes for the
psrt phenotype, Tip30/Cc3 and Prmt3. A search of the human genome sequencing

database in llp14-15, the region of homology, has provided one additional candidate
gene:

GLYT2.

Two of these genes have been evaluated for their suitability as

candidates for the psrt phenotype. All three of these candidates are described in detail
in Chapter VI (Description of Candidate Genes).
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CHAPTER VI
DESCRIPTION OF CANDIDATE GENES

INTRODUCTION
There are three candidate genes that have been identified for the psrt phenotype:
Tat-interacting protein 30 kDA (Tip30), glycine transporter type 2 (Glyt2), and protein
arginine N-methyltransferase 3 (Prmt3). What follows is a description of each of the

three candidates, and a discussion of the function of the proteins encoded by these
genes.

Tat-interactingprotein 30 kDa (TIP30)

Tat-interacting protein 30 kDa (TIP30) is a cellular protein that interacts with
the trans-activator of transcription (TAT) protein, a transcription factor encoded by
HIV-1 (Xiao et al., 1998).

TAT promotes transcriptional elongation by RNA

polymerase II (RNAP II) and requires multiple cofactors, including TIP30, CDK 9,
cyclin T, Tat-SFl, P-TEFb, TFIIH, TAK, (human) SPT5, and CA150 (Herrman and
Rice, 1995; Zhou and Sharp, 1995; Cujec et al., 1997; Keen et al., 1997; Sune et al.,
1997; Xiao et al., 1998; Yank:ulovand Bentley, 1998; Zhou et al., 1998; Jeang et al.,
1999; Kim et al., 1999). Tat is unique in that it binds to an RNA, rather than a DNA,
ligand during transcription (Zhou and Sharp, 1995; Parada and Roeder, 1996). Tat
binds to TAR, the trans-activation response region, which is a stem-loop structure near
the initiation site of the HIV-I transcript (Zhou and Sharp, 1995; Yank:ulovand Bentley,
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1998). Tat has been shown to have other functions as well, including an involvement in
HIV-1 reverse transcription (Harrich et al., 1997).
TIP30 is a member of the short-chain dehydrogenase/reductase (SDR) family
(Baker, 1999). It contains a

pap fold

near the amino terminus as well as other

structural features conserved among members of the SDR family (Baker et al., 2000).
TIP30 is the same as the protein called CC3, a known suppressor of metastasis (Liu et
al., 1999; Shtivelman, 1997). Human CC3 is ubiquitously expressed in tissues as well

as in various cell lines, including the classic small cell lung carcinoma (c-SCLC) cell
line. However, no CC3 expression has been demonstrated in variant small cell lung
carcinoma (v-SCLC) cell lines, which exhibit very aggressive metastatic behavior. It
has been hypothesized that CC3 functions as a tumor suppressor by promoting
apoptosis (Shtivelman, 1997).

TIP30/CC3 has recently been identified as a

serine/threonine kinase, and is involved in the Tat-dependent phosphorylation of the Cterminal domain of the largest RNAP II subunit. This kinase activity is necessary for
TIP30/CC3 to function both as a transcriptional cofactor and in regulating apoptosis
(Xiao et al., 2000).
The genomic sequence of Tip30/Cc3 has not been published; however, a similar
cDNA, named TC3 (for truncated CC3), has been described in human. The TC3 and
CC3 proteins share a similar N-terminal domain; however, TC3 has a unique, shorter Cterminus. While CC3 is a tumor suppressor that functions through activation of the
apoptotic pathway, TC3 is a tumor promoter that strongly inhibits apoptosis. The TC3
protein is highly unstable and, therefore, short lived. It has been postulated that CC3
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and TC3 arise from alternatively spliced transcripts from the same genomic locus since
a large portion of their N-terminal domains are identical (Whitman et al., 2000);
however, sequencing data from this project dispute this claim.

Glycine transporter type 2 (GLYT2)
Neurotransmitter transporters are membrane-bound proteins located either in the
plasma membrane or in the synaptic vesicle membrane. There are three types of these
transporters:

the Na+/CC and K+/Cl- dependent transporters located in the plasma

membrane, and the pH or H+-dependent transporters located in the membrane of the
synaptic vesicle (Lesch et al., 1996).

Neurotransmitter transporters establish and

mediate the interplay between excitation and inhibition, and abnormal neurotransmitter
transport has been shown to cause nerve dysfunction and damage (Liu and Edwards,
1997; Morrow et al., 1998). Glycine transporter type 2 (GlyT2) is a member of the
Na+/Cr dependent family of neurotransmitter transporters and is one of two glycine
transporters identified in humans.

It is involved in the reuptake of glycine at the

synaptic cleft through a ligand-gated Cl- channel (Amara & Kuhar, 1993 cited in
Aubrey et al., 2000; Morrow et al., 1998).
Glycine

and

y-aminobutyric

acid

(GABA),

the

maJor

inhibitory

neurotransmitters of the vertebrate brain stem and spinal cord, keep the postsynaptic
membrane polarized, thereby suppressing synapse firing.

In contrast, glutamate and

other excitatory neurotransmitters function to open Na+ channels and depolarize the
presynaptic membrane until the action potential is reached and the synapse fires
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(Reckling et al., 2000; Alberts et al., 1996). GABA and glycine are both considered
fast neurotransmitters because of their kinetics; however, the kinetics of GABA
suppression is different from glycine suppression, since GABA has a more prolonged
effect than glycine (Nicoll and Malenka, 1998). Although they have separate receptors
and transporters, GABA and glycine are co-released from the same vesicles at the
inhibitory synapses of spinal neurons (Jonas et al., 1998).
The GLYT2 protein contains six consensus protein kinase C-dependent
phosphorylation sites as well as five N-linked glycosylation sites (Martinez-Maza et al.,
2001; Morrow et al., 1998). It has been demonstrated that the glycosylation status of
the protein affects its subcellular localization (Martinez-Maza et al., 2001). Like other
members of the Na+/Cr dependent neurotransmitter transporter family, GLYT2 contains
12 transmembrane domains, with domain ill being primarily responsible for the
transport activity of both the substrate and the co-transported Na+ and er ions (Ponce et
al., 2000). GLYT2 co-localizes with the strychnine-sensitive glycine receptors in the
brain stem, spinal cord, and cerebellum (Morrow et al., 1998; Aubrey et al., 2000). It
co-immunoprecipates with Syntaxin IA, a SNARE (soluble N-ethylmaleimide-sensitive
factor attachment protein receptor) protein involved in both intracellular membrane
trafficking and the regulation of various ion channels. Syntaxin IA has also been
shown to interact with GATl, a GABA transporter, and GLYTl, a type-I glycine
transporter.

When GLYT2 is bound to syntaxin IA, the normal GLYT2 protein

trafficking pattern in the cell is upset. This causes GlyT2 to be improperly distributed
in the plasma membrane, thereby interfering with the transport of glycine (Geerlings et
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al., 2000). Furthermore, a yeast two-hybrid analysis using GlyT2 as bait has identifed
unc-33 like phosphoprotein 6 (Ulip6) as a protein interacting with GLYT2. Ulip6 is
expressed in embryonic and postnatal brain and spinal cord and is believed to be
involved in neuronal differentiation and axon growth (Horiuchi et. al., 2000).
Therefore, GLYT2 is a protein involved in neural development and function in several
ways.
In humans, the GLYT2 gene produces a single, 9.5-kb mRNA transcript detected
by northern hybridization in medulla, cerebellum, and spinal cord (Morrow et al.,
1998). The gene maps to human chromosome llp15.1-15.2

(Morrow et al., 1998),

which is homologous to the psrt region of Mmu 7. Several polymorphisms have been
reported in the human gene; however, the effect(s) of these polymorphisms on
neurophysiology is unknown (Evans et al., 1999).

Protein arginine methyltransferase 3 (Prmt3)
A thorough discussion of Prmt3 as a candidate for the psrt phenotype should
include an overview of the process ofmethylation.

What follows is such an overview,

with a description of enzymatic methylation in general followed by a review of protein
arginine methylation, including a discussion of the functional roles of the process at the
cellular and organismal levels, as well as in vivo substrates and protein arginine
methyltransferase enzymes.
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1. Enzymatic Methylation
Methyltransferases are an important class of enzymes that catalyze the transfer
of a methyl group to a substrate. The universal methyl donor for these reactions is Sadenosylmethionine (AdoMet, or SAM), which is a methionine with an adenosine
attached to the sulfur atom on the side chain; however, there are many types of methylaccepting substrates.

DNA methyltransferases are a well-studied class of enzymes

responsible for methylating various positions on cytosine and adenine nucleotides
(Bussiere et al., 1998; Labahn et al., 1994). A methyltransferase that modifies mRNA,
and two small molecule methyltransferases that modify catechol and glycine, have also
been described (Bussiere et al., 1998). Several types of protein methyltransferases are
known, as well (Gary and Clarke, 1998).
Despite the diversity of functions performed and substrates utilized by the
different methyltransferase enzymes, all known AdoMet-dependent methyltransferases
operate via a SN2 (bimolecular nucleophilic substitution) reaction mechanism (Zhang et

al., 2000).

They contain a signature methyltransferase domain composed of four

conserved regions of homology:

motifs I, post-I, II, and III.

These motifs are

responsible for binding AdoMet and catalyzing the methyl transfer (Weiss et al., 2000).
They appear in the same order and are separated by a characteristic number of residues.
Motifs I and post-I are involved in AdoMet binding, motifs II and III interact with each
other, and motifs I, II, and III are involved in forming the central 13-sheet, a structural
element common to all methyltransferases (Niewmierzycka and Clarke, 1999).
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2. Protein Methylation
In eukaryotes, proteins can be methylated either on the oxygen molecule in the

carboxyl group or on the nitrogen molecule(s) in the side chain. Only three amino acid
residues are modified in eukaryotes by methylation:

arginine, histidine, or lysine
In

(Aletta et al., 1998; Sundarraj and Pfeiffer, 1973; Gary and Clarke, 1998).

prokaryotes, it has been shown that a methyl group can be transferred via an
esterification reaction to the y-carboxyl group of glutamic acid residues (Aletta et al.,
1998).
There have been three types of protein methylases described: those that transfer
the methyl group (from AdoMet) to an arginine residue in the substrate, those that
transfer it to a C-terminal carboxyl group of a histidine residue, and those that transfer
the methyl group to the E-amino group of a lysine residue. These are called protein
methylase I, II, and III, respectively (Sundarraj and Pfeiffer, 1973) (Figure VI-1).
Protein methylase I, a protein arginine methyltransferase (PRMT), is the enzyme
responsible for methylating any of the guanidino nitrogens present in arginine residues.
PRMT genes have been identified and cloned in several organisms, including human,

Saccharomyces

cerevisiae and Schizosaccharomyces pombe,

Arabidopsis,

and

Caenorhabditis elegans. In addition, expressed sequence tags (ESTs) from at least six
other organisms (including Drosophila melanogaster, Xenopus laevis, sea urchin and
zebrafish, as well as rice and tomato) show similarity to PRMTs (Zhang et al., 2000).
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3. Functional Roles of Arginine Methylation
The precise biochemical role that protein arginine methylation plays in the cell
has not yet been determined; however, it is believed to be responsible, at least in part,
for a variety of processes.

Most of the known in vivo targets of protein arginine

methylation are proteins involved in some way with RNA, either through directly
binding the RNA or through involvement with the ribosome (Najbauer et al., 1993; Liu
and Dreyfuss, 1995; Gary and Clarke, 1998). Certain proteins contain an RGG (or
GAR) domain, which has an abundance of arginine and glycine residues and is the
specific substrate for several protein arginine N-methyltransferases.

This domain has

been shown to modulate protein-protein and protein-nucleic acid interactions (Bouvet et

al., 1998; Gary and Clarke, 1998). Methylarginine-containing domains have also been
shown to be responsible for the binding specificity of certain proteins (Plotnikov et al.,
2000). It has been postulated that the presence of methylarginine residues could affect
the dynamics of ligand-substrate interactions, altering either the stereochemistry of the
process, the hydrogen bonding interactions occurring between the modified protein and
its substrate(s), or both (Mears and Rice, 1996). Therefore, the methylation of arginine
residues is believed to play a role in the intermolecular dynamics of ligand-substrate
binding, including both protein-nucleic acid and protein-protein interactions.
The modification of arginine residues has also been shown to affect a protein's
susceptiblilty to proteolysis. Methylated heterogeneous nuclear ribonuclear protein Al
(hnRNP Al) is more susceptible to trypsin digestion than the unmethylated protein
(Rajpurohit et al., 1994a), while the methylated forms of other hnRNPs have been
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shown to confer resistance to proteolytic cleavage (Bedford et al., 2000). The myelin
basic protein (MBP) normally contains 19 arginine residues, only one of which is
modified by methylation.

It has been shown that MBP containing this single

methylarginine residue is more resistant to trypsin digestion than is the unmethylated
MBP (Brostoff and Eylar, 1971). On the other hand, MBP containing citrullines in
place of the methylarginine and the other unmodified arginines is proteolytically
degraded by cathepsin D more quickly than the non-citrullated MBP. Citrulline, like
methylarginine, is a posttranslationally modified arginine; however, citrulline is
modified by deamidation, a different process.

Furthermore, there is a positive

correlation between number of citrulline residues in the protein and the rate of
enzymatic degradation (Cao et al., 1999). Therefore, the modification of arginine
residues, either through the process of protein arginine methylation or through
deamidation, can effectively and substantially alter the protein-protein interactions
involved in catalytic proteolysis.
Protein arginine methylation has also been shown to be involved in subcellular
localization.

Proteins containing methylarginine residues are found in various

compartments within the cell: some are located in the nucleus, some are cytosolic, and
others are capable of shuttling between the nucleus or nucleolus and the cytoplasm. It
has been demonstrated that the methylarginine-containing domain of certain proteins is
necessary for them to be localized to the proper subcellular compartment (SchmidtZachmann and Nigg, 1993; Burgess et al., 1991; Gary and Clarke, 1998; Nichols et al.,
2000). Similarly, it has been shown in Saccharomyces cerevisiae that protein arginine
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methylation is required for certain hnRNPs to be exported from the nucleus to the
cytoplasm (Shen et al., 1998).
It has long been reported that the posttranslational acetylation of certain lysine

residues in the histones is responsible for regulating gene expression. The acetylation
of the histones effects a change in the structure of chromatin, causing it to "loosen",
thereby allowing the cellular machinery easier access to DNA (Pennisi, 1997; Rundlett
et al., 1996). It has been suggested that a similar posttranslational modification, the

methylation of arginine residues in the histone proteins, may also be at least partially
responsible for altering the structure of chromatin (Chen et al., 1999; Hagmann, 1999).
There have been numerous protein deacetylases identified and studied in eukaryotes;
however, no protein arginine demethylase has yet been identified (Smith et al., 1999),
although the existence of one has been proposed (Young and Waickus, 1987). Thus it
appears that methylation, unlike acetylation, may be an irreversible process. Therefore,
gene regulation through histone methylation may or may not follow the same paradigm
as gene regulation through reversible acetylation. It should be noted, however, that the
histones are complex proteins that are the targets of numerous epigenetic modifications
(Hagmann, 1999); therefore, it will be difficult to determine the exact effect(s) that
protein arginine methylation may have on these proteins, especially since these effects
could be subtle.
Along these same lines, there is some evidence to indicate that protein arginine
methylation may be connected to development. In the rat, methyltransferase activity
appears to be developmentally regulated. Protein arginine methyltransferase activity is
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highest in fetal brain, declining steadily after birth (Paik et al., 1972 cited in Gary and
Clarke, 1998). These results suggest a possible connection between protein arginine
methylation and development, either in the developmentally regulated expression of
genes or in some other aspect of growth and development.
It has also been hypothesized that there may be a link between protein arginine

methylation and metastasis (Gu et al., 1999; Pennisi, 1997). Elevated levels of protein
arginine N-methyltransferase activity have been reported in highly proliferating tissues,
and there is a correlation between the level of methyltransferase activity and the degree
of proliferation (Rajpurohit et al., 1994b; Scorilas et al., 2000). While there are three
mRNA transcripts of protein arginine methyltransferase 1 (Prmtl) present in normal
mammary cells, two of these transcripts are significantly down-regulated in breast
cancer cells (Scorilas et al., 2000). In addition, a 20 kDa protein of unknown function
has been isolated from four different cancer cell lines and shown to be methylated at
multiple arginine residues; however, this same protein is present but unmethylated in
normal colon cells (Gu et al., 1999). Although not conclusive, this evidence suggests
the involvement of protein arginine methylation in cellular proliferation and metastasis.
The human Janus kinase binding protein 1 (JBPl) and its yeast homolog, Hsl7p,
contain a methyltransferase motif and have been shown to exhibit protein arginine
methyltransferase activity (Pollack et al., 1999; Lee et al., 2000). JBPl binds to Janus
kinase (Jak), which is involved in the Jak-Stat (signal transducers and activators of
transcription) pathway (Pollack et al., 1999). PRMTl, a mammalian protein arginine
methyltransferase, was first identified because of its ability to interact with the
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intracytoplasmic domain of the interferon-a,p receptor, which is also involved in the
Jak:-Stat pathway (Abramovich et al., 1997). The Jak:-Stat pathway is involved in both
signal transduction and cell cycle regulation, suggesting that methyltransferases may
play a role in cell signaling and/or cell cycle regulation (Pollack et al., 1999).
The methylation of a single arginine residue, arginine-I 07 (R-107), in the
myelin basic protein (MBP) is critical to the function of MBP within the myelin
membrane. It has been shown that arginine methylation is involved in maintaining the
integrity of the myelin sheath, and the inhibition of MBP-specific methyltransferase
activity during myelinogenesis leads to dysmyelination (Amur et al., 1986; Kim et al.,
1997b). MBP undergoes several posttranslational modifications, all of which affect the
charge microheterogeneity of the mature protein. These modifications, one of which is
methylation, alter the hydrophobicity of the protein which, in turn, affects the ability of
the MBP to interact with, and bind to, the lipids in the myelin membrane (Zand et al.,
1998; Boggs et al., 1999). Methylated MBP is less cationic than unmethylated MBP
(Ghosh et al., 1991), and the methylation of MBP alters the thermodynamics of the
MBP-myelin membrane association by decreasing the free energy of the protein-lipid
interaction by 0.9 kcal/mole (Young et al., 1987). The methylarginine residue in MBP
occurs near the N-terminus, and it has been shown in vitro that the N-terminal half of
the MBP interacts with lipids more than the C-terminal half of the protein (Boggs et al.,
1999). Therefore, protein arginine methylation is involved in the development and
maintenance of the mammalian central nervous system.
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Protein arginine methylation has also been implicated in a number of
autoimmune diseases. There has been some evidence presented to link the methylation
of R-107 in the MBP to multiple sclerosis (MS).

MS is a neurological disease

characterized by an erosion of the myelin sheath and is believed to be caused by an
autoimmune attack on myelin. It has been suggested that the autoantigen responsible
for the disease is MBP itself (Moscarello et al., 1994). Once the myelin has been
disrupted, MBP is broken down in the body and excreted in the urine (Whitaker, 1998;
Whitaker et al., 1999). Analysis of the dimethylarginine (Me2 Arg) content of MBP
breakdown products in the urine of chronic MS sufferers confirms the presence of 2033% less Me2 (sym)Arg than would be expected (Rawal et al., 1995b).

Since

methylated MBP is resistant to enzymatic digestion, it has been suggested that the rate
of MBP degradation and, therefore, the progression of the disease, may be related to the
methylation status of the R-107 in the protein (Kim et al., 1997b).
It has also been shown that, based on the morphology of the myelin membrane

and the level of charge microheterogeneity in the MBP, the myelin present in MS
patients is developmentally immature (Moscarello et al., 1994). The composition of the
MBP in myelin changes throughout development. In the mouse and other rodents,
where several alternatively spliced isoforms of MBP exist, the temporal expression
pattern of each isoform is unique (Barbarese et al., 1978; Carson et al., 1983; Kruger et
al., 1999). It has also been shown that the amount and type of MBP methylation in
young rodent brains is different from that found in mature brains (Rawal et al., 1995a).
MBP isolated from normal adult rat brains contains MeArg and symmetrical
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dimethylarginine (Me 2(sym)Arg).

In young rat brains, however, MBP contains an

additional isomer, asymmetrical dimethylarginine (Me 2(asym)Arg), which is not found
in adult brains (Rawal et al., 1995a). It is not clear if the immature myelin present in
MS patients is either the cause, or the result, of the disease; in either case, the etiology
of the disease includes demyelination, which may be linked to abnormal MBP
methylation.
In addition to its possible role in MS, MBP is the primary autoantigen associated

with allergic encephalomyelitis (Eylar and Thompson, 1969).
methylarginine

There are other

containing proteins that have been associated with autoimmune

diseases, as well. Fibrillarin, which contains several methylarginine residues, was first
identified because of its immunoreactivity to scleroderma antibodies (Ochs et al., 1985).
Antibodies from patients with systemic lupus erythematosus have been used to identify
three

methylarginine-containing

protein autoantigens

involved

in this disease:

heterogeneous ribonucleoprotein Al, nucleolin, and Sm protein D1 (Minota et al.,
1991; Jensen et al., 1988; Brahms et al., 2000).

On a separate, but related, note:

peptides containing citrulline, a different posttranslational arginine modification, have
been implicated in rheumatoid arthritis, another autoimmune disease (Schellekens et al.,
1998). Therefore, there appears to be a link between arginine modification and the
etiology of certain autoimmune diseases.
Protein arginine methylation is an important posttranslational modification that
is believed to play a variety of roles in the cell and in the mammalian central nervous
and immune systems. Proteins containing methylarginine residues are associated with
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substrate-ligand
interactions.

binding,

including

protein-nucleic

acid

and

protein-protein

They are also associated with signal transduction, development, the

regulation of gene expression and cellular proliferation, nervous system function, and
the etiology of certain autoimmune diseases.

In addition, methylarginine-containing

domains have been shown to be necessary for the proper subcellular localization of
many proteins. Although the precise role(s) that protein arginine methylation plays has
yet to be definitively determined, it is clear that the processes associated with this
modification

are numerous and diverse, and necessary for proper cellular and

organismal function.
4. In vivo Substrates for Protein Arginine Methyltransferases
There

are

methyltransferases.

several

known

in

vivo

substrates

for

protein

argmme

Some are localized in the nucleus or nucleolus, some are cytosolic,

and others are capable of shuttling between the nucleus/nucleolus and the cytoplasm.
The biological function of many of these substrates is well known, while the role of
others has yet to be elucidated.

Most of the known substrates are either

monomethylated or asymmetrically dimethylated; however, two substrates have been
identified that contain symmetrically dimethylated arginine residues.

A. Asymmetrically Methylated Substrates
1. Yeast Hrp 1p Protein
Heterogeneous

nuclear ribonuclear

proteins

(hnRNPs)

proteins involved in the complex process of RNA maturation.

are RNA-binding

There are at least 20
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hnRNPs in the eukaryotic nucleus, and most of these have been shown to contain
methylarginine

residues (Liu and Dreyfuss, 1995).

The Saccharomyces cerevisiae

Hrp 1p protein is an hnRNP involved in the polyadenylation and processing of the 3'
end of mRNAs as well as mRNA export from the nucleus. Although it is predominately
located in the nucleus, it has been found to shuttle between the nucleus and the
cytoplasm.

Hrp 1p contains asymmetrically dimethylated arginine residues; however, it

has been shown that the methylation of the arginine residues has little or no effect on its
ability to bind RNA (Valentini et al., 1999).

2. Heterogeneous Nuclear Ribonuclear Protein Al
The heterogeneous nuclear ribonuclear protein Al (hnRNP Al) is one of the
most

abundant

of the multiple polypeptide

ribonucleoprotein

components

of the eukaryotic

40S

particle. It contains a unique nuclear localization signal sequence that

also functions as a nuclear export signal. Although hnRNP Al is primarily localized in
the nucleus, it shuttles between the nucleus and the cytoplasm via a temperaturesensitive pathway.

Therefore, it is believed that hnRNP Al is involved in shuttling

mRNA

from the nucleus to the cytoplasm

molecules

Alternatively spliced transcripts for the human HNRNPAl

(Michael

et al., 1995).

gene can encode for at least

two protein isoforms (Buvoli et al., 1988; Biamonti et al., 1989).

The protein itself

contains a glycine- and arginine-rich (GAR) region, with four known sites for protein
arginine methylation near the C-terminus (Williams et al., 1985; Rajpurohit et al.,
1994b; Kim et al., 1997c ). An analysis of the modified arginine residues from this
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region reveal both monomethylarginine and asymmetrically dimethylated argmme
(Rajpurohit et al., 1994b).

3. Poly(A)-binding Protein II
Poly(A)-binding protein II (PABP2) is a protein that binds to the polyadenylated
tails of nascent mRNA transcripts. Although found predominately in the nucleus, it has
the capability to shuttle between the nucleus and the cytoplasm (Calado et al., 2000;
Smith et al., 1999). It contains an RNA-binding domain, an acidic N-terminus, and a
basic C-terminus containing 13 asymmetrically dimethylated and two monomethylated
arginine residues (Nemeth et al., 1995; Smith et al., 1999). In the rat, the Pabp2 gene
produces a 9.5-kb transcript that is expressed in brain, kidney, liver, lung, and testis
(Muller et al., 1992). Mutations involving expansion repeats in the human PABP2 gene
cause the autosomal dominant form of oculopharyngeal muscular dystrophy (OPMD), a
late-onset neurological disease (Calado et al., 2000).

4. Fibrillarin
Fibrillarin 1s a nucleolar protein that is a part of the small nuclear
ribonucleoprotein particle (snRNP). It is believed to be involved in processing RNA,
specifically by shortening the preribosomal RNA from the 5' end (Aris and Blobel,
1991). Fibrillarin contains at least six arginine residues that have been shown to be
asymmetrically dimethylated, all of which are contained in the GAR region of the Nterminal domain (Gary and Clarke, 1998; Aris and Blobel, 1991). Fibrillarin is present
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in all eukaryotic species examined thus far, and fibrillarin genes have been cloned in

Saccharomyces cerevisiae andXenopus laevis (Aris and Blobel, 1991).

5. Nucleolin and U20
Nucleolin, like fibrillarin, is a localized in the nucleolus. It is a phosphoprotein
involved in the biogenesis and maturation of ribosomes (Srivastava et al., 1990).
Unlike fibrillarin, however, nucleolin has the ability to shuttle between the cytoplasm
and the nucleus. For this reason, it is believed that nucleolin is involved not only in the
assembly of the ribosomes, but also in the export of pre-ribosomal particles from the
nucleolus to the cytoplasm. The C-terminus of nucleolin contains an RGG domain,
which has an abundance of arginine and glycine residues. This RGG domain, which
contains

asymmetrically

dimethylated arginine residues,

functions to modulate

interactions between nucleolin and several ribosomal proteins (Bouvet et al., 1998). It
is also required for proper subcellular localization (Schmidt-Zachmann and Nigg,
1993).

The nucleolin gene is well conserved across several species; it is present in

chicken and yeast as well as in several mammalian species, where it is ubiquitously and
constitutively expressed (Srivastava et al., 1990).

The nucleolin gene is also

responsible for producing U20, a short (80 nt) RNA transcript which, like nucleolin, is
localized in the nucleus.

U20 is immunoprecipated by antibodies to fibrillarin;

therefore, fibrillarin and U20 may interact in vivo. U20 transcripts, which contain a 21
nt stretch that is complementary to the sequence of the 18S rRNA, have been detected
in all vertebrates examined so far (Nicoloso et al., 1994).
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6. Histones
The histone proteins are another class of proteins that have been shown to be in
vivo substrates for protein methyltransferases (Casellas and Jeanteur, 1978). Specific

amino acid residues on the histones can be modified by various biological processes,
including phosphorylation, acetylation and methylation.

Although the histones are

normally methylated on lysine residues by a protein lysine methyltransferase, it has
been shown that arginine residues on various histone proteins are substrates for protein
arginine methyltransferases (Hagmann, 1999). Arginine residues on histones Hl, H2,
H3, and H4 can be methylated (Frost et al., 1989; Gary and Clarke, 1998; Chen et al.,
1999; Disa et al., 1986) even though histones H2B, H2A and H3 are devoid of the GAR
motif that has been shown to be the target of arginine methylation in other proteins.
These non-GAR histones do, however, contain multiple arginine residues that could
serve as methyl acceptors (Gary and Clarke, 1998). There have been conflicting reports
about the product of protein arginine methylation in the histones; therefore, it is unclear
if the in vivo product of this process is monomethylarginine, asymmetrically
dimethylated arginine, symmetrically dimethylated arginine, or some combination of
the three species (Gary and Clarke, 1998).

7. Basic Fibroblast Growth Factor
Basic fibroblast growth factor (bFGF), or FGF-2, is a mitogen present m
mammalian cells (Gary and Clarke, 1998). FGF-2 is a heparin-binding protein that is
believed to be involved in angiogenesis, osteogenesis, tissue repair, and blood pressure

62

regulation (Abraham et al., 1986; Burgess et al., 1991; Dono et al., 1998; Montero et

al., 2000).

Mice lacking Fgf-2 display a complex phenotype indicative of the

pleiotropic nature of the protein. Although Fgf-2 null mice are viable, fertile, and
appear morphologically normal, they display structural defects in several areas of the
central nervous system, including the cerebral cortex, the hippocampus, and the cervical
spinal cord.

In addition, Fgf-2 deficient mice are hypotensive and have a retarded

healing response to skin injury (Dono et al., 1998; Ortega et al., 1998). The Fgf-2 gene
encodes multiple transcripts through alternative splicing events (Kurokawa et al., 1987).
The high molecular weight (HMW) isoforms of the FGF-2 protein have an amino
terminal extension containing an RGG domain with multiple sites for arginine
methylation, and the arginine residues in this region are asymmetrically dimethylated
(Klein et al., 2000; Gary and Clarke, 1998; Burgess et al., 1991). It has been suggested
that this N-terminal domain, containing the methylarginine residues, is responsible for
both the nuclear localization and the binding specificity of the HMW FGF-2 isoforms
(Burgess et al., 1991; Plotnikov et al., 2000).

8. ICP27
The ICP27 protein encoded by the herpes simplex virus type 1 (HSV-1) contains
one or more methylarginine residues in a glycine- and arginine-rich motif similar to an
RGG box. ICP27 is an immediate-early (IE, or a.) protein that is primarily localized in
the nucleus; however, it has been shown to shuttle between the nucleolus and the
cytoplasm (Mears and Rice, 1996; Sandri-Goldin, 1998). ICP27 is involved in the
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polyadenylation and splicing of RNA; it stimulates 3' RNA processmg of
polyadenylated viral proteins while inhibiting the splicing of host mRNAs (SandriGoldin, 1994).

The RGG-like motif in ICP27, where the methylarginine(s) is/are

located, is required for the protein to bind to RNA (Sandri-Goldin, 1998). Although
this motif is not necessary for nuclear localization, it is required for the proper
localization to the nucleolus (Mears et al., 1995).

9. Other Proteins
There are several other proteins that function as substrates for Type I protein
arginine methyltransferases in vivo. Interleukin enhancer-binding factor 3 (ILF3) is a
protein whose C-terminal is rich in glycine, arginine, and serine residues. It is a nuclear
protein that is a substrate for, and co-immunoprecipitates with, PRMTl (Tang et al.,
2000). The yeast essential Npl3p (nucleosome assembly protein 1-like 3) protein is an
RNA binding protein that shuttles between the nucleus and the cytoplasm. It contains
multiple RGG motifs in its C-terminus, and evidence suggests that these C-terminal
RGG motifs contains one or more methylarginine residues (Henry and Silver, 1996;
Siebel and Guthrie, 1996). Sam68, a proposed adapter protein for Src kinases, contains
a proline-rich motif flanked by a GAR domain containing asymmetrically dimethylated
arginine residues (Bedford et al., 2000).

Cytochrome c from Euglena gracilis is a

cytosolic protein containing a single methylarginine residue near the N-terminus
(Farooqui et al., 1985).

In addition, Garl (glutamic acid-rich protein 1), Nopl

(nucleolar protein 1), and Sbpl (skeleton binding protein 1) are all GAR-containing
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proteins which have been shown to be methyl acceptors in vivo (Frankel and Clarke,
1999).

B. Symmetrically Methylated Substrates
1. Sm Proteins D 1 and D3
The Sm proteins D 1 and D3 are two of the numerous protein constituents of the
spliceosome, a nuclear protein complex involved in the processing and splicing of premRNA molecules. In all eukaryotes except yeast, these proteins contain RG dipeptide
repeats in their C-termini. These RG dipeptides, which are different from the RGG or
GAR motifs found in other methylated substrates of PRMTs, are the site of in vivo
arginine methylation. The human DI and D3 proteins contain nine and four arginine
residues, respectively, in their C-terminal RG dipeptide motif, and all of these arginine
residues exist exclusively as symmetrical dimethylarginine (Brahms et al., 2000).

2. Myelin Basic Protein
The myelin basic protein (MBP) is one of the major protein constituents of the
myelin membrane. It is a highly basic protein and is the antigen responsible for allergic
encephalomyelitis (Eylar and Thompson, 1969).

In solution, the MBP molecule has

very little secondary structure. It is considered to be highly unfolded with an open and
extended rod-like conformation, and it is this lack of secondary structure that confers its
unusual resistance to denaturation (Eylar and Thompson, 1969). MBP interacts in vivo
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with acidic lipids to form the myelin sheath, and this lipid-bound state induces
additional structural characteristics in the molecule (Lees and Brostoff, 1984).
Although MBP exists as a single protein in humans (Carnegie, 1970 cited in
Kim et al., 1997b), the MBP of rodents is actually several related proteins arising from
alternatively spliced transcripts of a single gene (deFerra et al., 1985; Takahashi et al.,
1985). There are four isoforms of MBP found in the central nervous system (CNS)
tissue of mice, ranging in mass from 14 kDa to 21.5 kDa (deFerra et al., 1985), with
each isoform having a unique expression pattern (Barbarese et al., 1978; Carson et al.,
1983; Kruger et al., 1999). In the mouse, MBP mRNA expression, MBP protein
synthesis, and myelination occur synchronously (Campagnoni et al., 1978; Carson et
al., 1983).

The MBP gene is a part of the larger Golli (gene expressed in the
oligodendrocyte lineage) transcription unit. The human and mouse Golli-MBP genes
have been cloned and sequenced; they contain 10 exons, the last 7 of which encode for
the various isoforms of MBP (Pribyl et al., 1993; Campagnoni et al., 1993). The GolliMBP gene maps to human chromosome 18q22-q23 (Kamholz et al, 1987);
coincidentally, the mouse homolog maps to Mmu 18 (Sidman, 1985). The MBP gene
contains a regulatory element located 50 nt upstream of the start of MBP transcription
(in exon 3 of the Golli-MBP gene), and this regulatory element is required for proper
temporal expression of the gene (Haas et al., 1995). There is also a RTS (mRNA
transport sequence) in the 3' untranslated region where hnRNPs bind and transport the
MBP mRNA to the distal end of the oligodendrocyte processes. Once there, it is
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incorporated into the myelin membrane and translated into protein (Hoek et al., 1998).
In the absence of thyroid hormone (which is involved in the regulation of

myelinogenesis), 9-cis-retinoic acid, the ligand for the retinoic acid receptor, can
stimulate transcription of the MBP promoter in rodent neural cell cultures (Pombo et

al., 1999).
MBP may serve a variety of functions in vivo.

In addition to its well-

characterized role in myelinogenesis, MBP can catalyze the polymerization and
assembly of clathrin baskets in vitro (Prasad et al., 1995). Human, bovine and rat
MBPs have all been shown to stimulate insulin and glucagon secretion from rat
pancreatic islets (Kolehmainen et al., 1990), and bovine MBP can inhibit the activity of
the histone-specific PRMT (Park et al., 1989). It has also been shown that bovine
MBP, when injected in Djungarian hamsters, causes a variety of effects in the endocrine
pancreas, associating with, and disrupting the integrity of, the plasma and intracellular
membranes (Kolehmainen and Sormunen, 1998).
MBP is a highly modified protein in vivo, and these post-translational
modifications serve to introduce charge microheterogeneity in the protein.

Myelin

isolated from CNS tissue contains any number of the following modifications:
phosphorylated serine and threonine residues; an acetylated N-terminal residue; the
deamidation of either a specific glutarnine residue or any of the 19 arginine residues;
and the methylation of a single arginine residue to produce both monomethylarginine
and symmetrically dimethylated arginine (Zand et al., 1998; Boggs et al., 1999; Young

et al., 1987; Baldwin and Carnegie, 1971a; Deibler and Martinson, 1973; Gary and
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Clarke, 1998).

The methylation of the arginine- I 07 residue appears to be a nearly

universal modification:

with the exception of carp, it has been found in every

mammalian and sub-mammalian vertebrate species studied (Kies et al., 1972; Deibler
and Martenson, 1973; Young et al., 1987).
There

are

methyltransferases.

several

known

in

vivo

substrates

for

protein

arginine

These posttranslationally modified proteins are involved in a

number of cellular processes, playing a variety of diverse roles. However, since the in

vivo substrates of several PRMTs are unknown, there are likely to be additional
substrates added to this list. Identification and comparison of these substrates will
undoubtedly lead to a deeper understanding of the mechanism of the PRMT reaction
and the role(s) that protein arginine methylation plays in the cell.

4. Protein N-Arginine Methyltransferases (PRMTs)
PRMT enzymes can be categorized into three subtypes: those that produce coN°-monomethylarginine and (asymmetric) co-N°,N°-dimethylarginine (often referred to
as Type I); those that produce co-N°-monomethylarginine and (symmetric) co-N°,N'G_
dimethylarginine (Type II); and those that produce o-N°-monomethylarginine

(Gary

and Clarke, 1998; Zobel-Thropp et al., 1998; Niewmierzycka and Clarke, 1999). The
third type of PRMT has only recently been identified and the protein is not well
characterized (Niewmierzycka and Clarke, 1999; Zobel-Thropp et al., 1998) (Figure

VI-1).
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Both Type I and Type II PRMTs are stimulated by cyclic AMP and inhibited by
S-adenosylhomocysteine (one of the products of the methylation reaction), sinefungin
(or adenosyl omithine, an antibiotic), adenosine dialdehyde, and catecholamines such as
epinephrine, norepinephrine, isoproterenol (Amur et al., 1986; Najbauer et al., 1992;
Park et al., 1989; Bussiere et al., 1998). The reactions involving these enzymes are
highly endothermic, requiring 12 ATPs per methyl group attached, and are apparently
irreversible (Gary and Clarke, 1998).

A. Type I PRMTs

There have been several Type I PRMTs identified and cloned in a wide variety
of eukaryotic organisms. All of them contain the signature methyltransferase motifs;
however, these enzymes can, and do, vary widely in their sequence outside these
regions.

There are only three PRMTs known so far in yeast, all of which have

homologs in other eukaryotes. There are five PRMTs cloned so far in mammals, and it
is possible that there are others that have not yet been identified.

1. Yeast Type I PRMTs
There have been two Type I methyltransferases identified from Saccharomyces
cerevisiae: RMTl (protein arginine methyltransferase 1) and RRP8. RMTl, which has

also been called HMTl (hnRNP methyltransferase 1), was identified by its homology to
the rat PRMTl gene (Gary et al., 1996; Gary and Clarke, 1998). RMTl contains four
conserved methyltransferase motifs: I, post I, II, and ill (Gary et al., 1996). It is a
nuclear protein that can methylate a number of substrates in vivo, including NPL3
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(nucleosome assembly protein I-like 3), a yeast hnRNP.

RMTl, unlike its NPL3

substrate, is not essential for cell viability (Henry and Silver, 1996). Crystallographic
evidence suggests that RMTl is oligomeric, existing as a hexamer in solution (Weiss et

al., 2000). Sequence analysis of the Rmtl gene reveals two regions of similarity to
other protein arginine methyltransferases: a stretch of 63 nucleotides showing strong
similarity to the SAM-binding motif of other methyltransferases, and a stretch of 48
nucleotides containing a nuclear localization signal (Henry and Silver, 1996).
RRP8 is another methyltransferase identified from Saccharomyces cerevisiae. It
is a nucleolar protein involved in pre-rRNA cleavage. Database searches indicate that
the C-terminal domain of RRP8 shows homology to proteins from a variety of
organisms, including Arabidopsis thaliana, Caenorhabditis elegans, Plasmodium

falciparum, Schizosaccharomyces pombe, and mammalian species as well (BousquetAntonelli et al., 2000).

RRP8 was first reported to contain only one signature

methyltransferase domain (Niewmierzycka and Clarke, 1999); however, further analysis .
confirms that it contains four conserved methyltransferase domains: I, post I, II, and ill
(Bousquet-Antonelli et al., 2000).

2. Mammalian Type I PRMTs
a. Protein arginine methyltransferase 1
Protein arginine methyltransferase 1 (PRMT 1) is the first mammalian PRMT to
be identified and cloned, and is responsible for the majority of PRMT enzyme activity
found in mammals (Lin et al., 1996; Tang et al., 2000). It was recovered using a yeast
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two-hybrid assay to identify proteins interacting with two similar proteins: TIS21, an
immediate-early protein of unknown function, and BTG 1, an antiproliferative protein
involved in chronic lymphocytic leukemia (Lin et al., 1996).

PRMTl was later

identified as a ligand for the Interleukin enhancer-binding factor 3 (ILF3), and has been
shown to methylate the C-terminus of1LF3 in vitro (Tang et al., 2000). It has also been
shown to interact with both the intracytoplasmic domain of the interferon-a,13 receptor
and the C-terminal AD2 activation domain of p 160 family of coactivators (Abramovich

et al., 1997; Koh et al., 2001).
PRMTl is classified as a type I protein arginine N-methyltransferase because of
its ability to form monomethyl- and asymmetrical dimethylarginine residues (Gary and
Clarke, 1998). The in vitro activity of PRMTl is strongly inhibited in the presence of
Tris and arginine but is unaffected by citrulline (a deamidated arginine), or the steroid
hormones (Frankel and Clarke, 2000; Scorilas et al., 2000). Conversely, ILF3 has been
shown to enhance the activity of PRMTl in vitro (Tang et al., 2000). Native PRMTl
can methylate the histones, hnRNP Al, and the poly(A)-binding protein II (PABP2)
(Lin et al., 1996; Smith et al., 1999). A Glutathione S-transferase (GST) fusion protein
containing the catalytic portion of PRMTl has been shown to methylate GST-GAR, an
artificial substrate containing GST fused to the glycine- and arginine-rich aminoterminal residues of fibrillarin (Tang et al., 1998). However, the GST-PRMTl protein
is unable to methylate either cytochrome c or the myelin basic protein (Lin et al., 1996;
Smith et al., 1999).
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PRMTl contains four highly conserved methyltransferase motifs: I, post I, II,
and ill (Lin et al., 1996). It is interesting to note, however, that PRMTl contains few
residues other than those identified in the conserved motifs (Frankel and Clarke, 1999).
PRMTl is an oligomeric protein, with reports of dimers and hexamers forming in
solution (Tang et al., 1998; Weiss et al., 2000). Although the exact function of the
PRMTl oligomers is unknown, it has been shown that dimerization is essential for
catalytic activity (Weiss et al., 2000).
The PRMTl gene contains 12 coding exons and spans an 11.2-kb genomic
interval (Scorilas et al., 2000). It maps to human chromosome 19q13.3 (Scott et al.,
1998; Scorilas et al., 2000). In the mouse it maps to chromosome 7, proximal to Ldh3,
Gas2, Snrpn, and Ube3a (Pawlak et al., 2000). This places Prmtl just proximal to the

p-deletion complex.

There are no human disease phenotypes or mouse mutations

known to map near these regions of the human or mouse genomes (Pawlak et al., 2000).
Prmtl produces a primary 1.282-kb mRNA transcript in the mouse (Pawlak et
al., 2000); however, at least two alternatively spliced transcripts, differing at their 5'

ends, have been detected (Scott et al., 1998; Scorilas et al., 2000).

Prmtl is

ubiquitously expressed in both rodent and human tissues (Lin et al., 1996; Scott et al.,
1998). Cell culture studies indicate that its activity is not required for cell viability;
however, Prmtl is constitutively expressed in mitogen-stimulated cells and is necessary
for early embryonic development in the mouse (Lin et al., 1996; Pawlak et al., 2000).
While all three mRNA transcripts of Prmtl are present in normal mammary cells, two
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of the transcripts have been shown to be significantly down-regulated in breast cancer
cells (Scorilas et al., 2000).
Of all the known mammalian protein arginine methyltransferase genes, only one
mutation, arising from a targeted retroviral insertion in the mouse prmtl gene, has been
described.

This prmtl mutation is essentially a null mutation, producing mRNA

transcript levels of only 1%, compared to the wild-type. The prmtl

knockout is

embryonic lethal, with death occurring at around day E6.5. Although the prmtl null
mutation is an embryonic lethal and PRMTl is responsible for the major proportion of
methyltransferase

activity in cells, it has been shown that PRMTl

activity is not

required for viability in mouse ES cells (Pawlak et al., 2000).

b. Protein arginine methyltransferase 2
The human PRMT2 gene was identified because of its similarity to the rat
PRMTl gene. It maps to human chromosome 21q22.3 (Scott et al., 1998; Katsanis et

al., 1997), and contains five conserved methyltransferase domains: I, post I, II, III, and
post III. It also contains a Src homology 3 (SH3) domain in its 5' end, making it unique
among all other previously identified members of the protein arginine methyltransferase
family (Katsanis et al., 1997). This SH3 domain is involved in protein-protein binding,
and methylarginine residues present in the protein substrate serve to reduce the level of
interaction between the SH3-containing ligand and its (methylarginine-containing)
substrate (Bedford et al., 2000).

The Prmt2 gene encodes a 2.8-kb mRNA that is

ubiquitously expressed, with slightly higher levels of expression in brain and placenta
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and lower levels in the liver and lung. There is some evidence to suggest that a larger
transcript may be present in breast and fetal heart, but this has not been conclusively
determined (Katsanis et al., 1997). It is interesting to note, however, that despite the
homology between PRMT2 and other protein arginine methyltransferase
members,

family

the PRMT2 protein has not been shown to have protein arginine

methyltransferase activity (Scott et al., 1998). Therefore, PRMT2 may be a structural,
but not functional, member of the PRMT family.

c. Protein arginine methyltransferase 3
Protein arginine methyltransferase 3 (PRMT3) is a type I protein arginine Nmethyltransferase that was recovered using a yeast two-hybrid assay to identify proteins
interacting with PRMTl, the first mammalian PRMT to be identified and cloned. The
PRMTl and PRMT3 proteins are 67% similar and 46% identical at the amino acid level
over the methyltransferase domain in their carboxy-terminal region; however, their
amino-terminal ends are dissimilar.

The N-terminus of PRMT3, which contains an

abundance of acidic residues, is called the N-terminal acidic amino acid-rich (NAR)
domain.

This NAR domain, which contains both a C2H2 zinc finger motif and a

tyrosine phosphorylation consensus sequence, shows no significant homology to other
known proteins (Tang et al., 1998).
The in vivo substrate for PRMT3 1s unknown; however, a glutathione Stransferase (GST) fusion protein containing the catalytic portion of PRMT3 has been
shown to methylate GST-GAR, an artificial substrate containing GST fused to the
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glycine- and arginine-rich amino-terminal residues of fibrillarin, which has multiple
arginine residues that serve as targets for methylation (Tang et al., 1998). PRMT3 and
PRMTl have both been shown to methylate arginine residues in the C-terminal domain
of poly(A)-binding protein II (PABP2), a protein believed to be involved in pre-mRNA
polyadenylation, in a methylation pattern consistent with the natural methylation of
PABP2 (Smith et al., 1999). The activity of PRMT3, unlike that of PRMTl, is
relatively unaffected by the addition of Tris to the in vitro reaction mixture; however,
both enzymes are inhibited by arginine, and both are unaffected by the addition of
citrulline, the posttranslationally deamidated adduct of arginine (Frankel and Clarke,
2000). In addition, there is a single 29 kDa substrate present in hypomethylated yeast
rmtl extracts that is methylated by GST-PRMT3, but not GST-PRMTl (Tang et al.,

1998).
PRMT3 is the only known enzyme with protein arginine N-methyltransferase
activity to have a zinc finger motif. PRMT3 binds zinc in a 1:1 stoichiometric ratio, and
it is this zinc finger domain of PRMT3 that appears to be responsible for conferring
substrate specificity (Frankel and Clarke, 2000).

GST-PRMT3 fusion proteins

containing only the catalytic portion of PRMT3 (without the zinc finger domain) will
methylate GST-GAR; however, it was found that the zinc-chelated form of PRMT3 was
required for the enzyme to recognize certain RNA-associated substrates in RATl cell
extracts (Frankel and Clarke, 2000). This is consistent with the notion that zinc fingers
are involved in protein-ligand binding, including protein-DNA, protein-RNA, and
protein-protein interactions (Mackay and Crossley, 1998).
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The Prmt3 gene produces a 2.4-kb mRNA transcript m the rat, which 1s
constitutively and ubiquitously expressed except in liver, where no expression 1s
detected via Northern blotting. Immunolocalization studies indicate that PRMT3 is
cytoplasmic, while PRMTl is localized in the nucleus. Although yeast two-hybrid data
indicate that PRMT3 has the potential to form homo-oligomers as well as heterooligomers with PRMTl, gel filtration analysis indicates that PRMT3 is monomeric
(Tang et al., 1998). Crystallographic evidence, however, indicates that the PRMT3 core
forms a homo-dimer when crystallized in the presence of a cofactor (Sadenosylhomocysteine).

These homo-dimers, and perhaps even PRMT1/PRMT3

hetero-dimers, may also be present in equilibrium with the monomers in vivo (Zhang et
al., 2000), but are unable to survive the process of cell disruption and gel filtration

analysis (Tang et al., 1998), possibly due to the thermodynamics of the
association/dissociation.

d.

Protein

argmme methyltransferase 4

/

Coactivator-associated

argmme

methyltransferase 1
Protein arginine methyltransferase 4 (PRMT4), or Coactivator-associated
arginine methyltransferase 1 (CARMI), is a protein that associates with the p160 family
of coactivators, which are nuclear hormone regulated transcription factors. In the
mouse, CARMI is expressed as a 3.8-kb mRNA transcript in a wide variety of tissues.
It shows 30 percent identity at the amino acid level to human PRMTl, and has been

shown to preferentially methylate histone H3.

CARMI regulates transcription by
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binding to the C-terminus of these p160 coactivators, in the AD2 activation domain.
Mutations affecting the ability of CARMl to bind S-adenosylmethionine have been
shown to significantly reduce both its methyltransferase and coactivator activities (Chen

et al., 1999; Chen et al., 2000; Stallcup et al., 2000).

e. Protein arginine methyltransferase 5 I Janus kinase binding protein 1
Protein arginine methyltransferase 5 (PRMT5) is a cytoplasmic, homooligomeric protein that was originally called Janus kinase binding protein 1 (JBPl)
(Frankel and Clarke, 2000; Rho et al., 2001). The human JBPl and its yeast homolog,
Hsl7p, contain a methyltransferase motif and have been shown to exhibit protein
arginine methyltransferase activity (Pollack et al., 1999; Lee et al., 2000). JBPl binds
to Janus kinase (Jak), which is involved in the Jak-Stat (signal transducers and
activators of transcription) pathway (Pollack et al., 1999). Yeast two-hybrid analysis
indicates that it also interacts with the nonstructural protein 3 encoded by the hepatitis C
virus (Rho et al., 2001). Although the in vivo substrate for the methyltransferase
activity of JBPl has not been identified, a GST-PRMT5 fusion protein has been shown
to methylate various Type I artificial substrates as well as MBP, a Type II substrate. It
has not been determined, however, if the dimethylation pattern of MBP methylated by
PRMT5 is symmetrical or asymmetrical; therefore, it is not clear if PRMT5 functions as
a Type I, Type II, or a Type I/II enzyme (Rho et al., 2001). The Jak-Stat pathway is
involved in both signal transduction and cell cycle regulation; therefore, the
involvement of a methyltransferase in this pathway suggests that protein arginine
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methylation may play a role in cell signaling and/or cell cycle regulation (Pollack et al.,
1999).

B. Type II PRMTs
Since the discovery, 30 years ago, of the methylation of a specific arginine
residue in the myelin basic protein (Baldwin and Carnegie, 1971b; Brostoff and Eylar,
1971) and the further identification of the modified residue as symmetrically
dimethylated arginine (Diebler and Martenson, 1973), scientists have been searching for
the enzyme responsible for this posttranslational modification. The enzymatic activity
of the MBP-specific PRMT has been isolated (Crang and Jacobson, 1982; Sundarraj
and Pfeiffer, 1973) and this enzyme activity is different from the activity of the histonemethylating PRMT (Kim et al., 1997b). However, a single protein representing this
activity has yet to be purified (Gary and Clarke, 1998).
The proposed kinetic mechanism for the enzyme involves AdoMet binding to
the enzyme first, followed by rapid-equilibrium binding to the substrate (Young and
Waickus, 1988). Studies of the Type II PRMT activity indicate that the preferred
sequence for methylation is an arginine flanked on either side by glycines, although the
enzyme retains at least partial activity when the N-terminal flanking glycine is
substituted by certain amino acids (Hyun et al., 2000). It was found that the MBPspecific PRMT requires a substrate of at least six residues for minimal activity, and that
methyltransferase activity increases as the length of the substrate peptide increases
(Ghosh et al., 1991; Hyun et al., 2000).
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In addition to the standard inhibitors of all PRMTs, the MBP-specific PRMT is

regulated by thyroid hormone and nitrous oxide (Amur et al., 1984; Amur et al., 1986).
It is interesting to point out that animals exposed to nitrous oxide for prolonged periods

of time show neurological effects due to demyelination (Amur et al., 1986).

In the

mouse, it has been shown that the activity of this methyltransferase is synchronized with
myelination (Crang and Jacobson, 1982; Kim et al., 1988; Rawal et al., 1991), and
inhibition of the MBP-specific PRMT leads to incomplete myelination (Amur et al.,
1986).

C. Other PRMTs
RMT2 is a umque methyltransferase that was identified through analyzing
SAM-binding sequence motifs found within the Saccharomyces cerevisiae genome. It
is considered unique because it can methylate the a-nitrogen of protein arginine residues
(Niewmierzycka and Clarke, 1999), a modification that was only recently described
(Zobel-Thropp et al., 1998). RMT2 contains the conserved methyltransferase motifs I,
post I, II, and ill, and it shares significant identity to the human guanidinoacetate Nmethyltransferase enzyme, which methylates the a-nitrogen atom in guanidinoacetate.
RMT2 homologs have been identified in Schizosaccharomyces pombe and Arabidopsis

thaliana, but not in higher eukaryotes or prokaryotes. In yeast, RMT2 is essential for
neither viability nor growth. Although the methyl-accepting substrate(s) for RMT2 has
not been identified, it is believed that the substrates are fully methylated and that
methylation occurs on the nascent proteins (Niewmierzycka and Clarke, 1999).
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CHAPTER VII
SEQUENCE AND EXPRESSION ANALYSES OF CANDIDATE GENES

ABSTRACT
Sequence analysis of B 179d14 identified two candidate genes for the psrt
phenoypte: Tip30/Cc3 and Prmt3. The Tip30/Cc3 and Prmt3 mRNAs are ubiquitously
and constitutively expressed. Sequence analysis of the Tip30/Cc3 cDNA indicates that
the sequence is identical in the control and the two mutant strains, 723SJ and 1060SJ.
There is evidence to suggest, however, that the Prmt3 gene is altered in the mutants.
Sequencing of cloned RT-PCR products failed to find a mutation in the 1060SJ Prmt3
cDNA,

but

temperature-gradient capillary

electrophoresis

(TGCE)

mediated

heteroduplex analysis strongly indicates that a mutation is present in the 3' end of the
transcript.

Sequencing of the 723SJ Prmt3 cDNA also failed to find a mutation;

however, the 5' end of the 723SJ allele could not be amplified, either through standard
RT-PCR or through 5' RACE. Southern blot analysis failed to verify a genomic
rearrangement or deletion. However, TGCE heteroduplex analysis also indicates a
mutation is present in the 3' end of the 723SJ transcript.

INTRODUCTION
In order to evaluate the candidacy of the two genes identified through sequence

analysis of BAC B 179d14, an expression analysis of each of the genes was performed
in the mutant and control animals. The tissue-specific and temporal mRNA expression

80

patterns, as well as the cDNA sequence, will be useful in determining whether either of
these genes could be responsible for the psrt phenotype.

MATERIALS AND METHODS
1. RNA Isolation
Total RNAs from brain were isolated using standard methods (Chirgwin et al.,
1979, Sambrook et al., 1989). Poly (At RNAs were isolated from total RNAs using
the Mini-Oligo (dT) Cellulose Spin Column Kit (5 Prime 3 Prime, Inc., Boulder, CO)
following the manufacturer's instructions.

2. RT-PCR
Approximately 5µ,gof total RNA were reverse transcribed in a 20 µ,L reaction
volume using Superscript II (Gibco BRL Life Technologies, Rockville, MD). A variety
of primer combinations were used to amplify the cDNAs from both the Prmt3 and the
Tip30/Cc3 genes (Table VII-1). Actin-specific primers (ORN 559/560) were used to

amplify a 520 bp fragment of /3-actin as the internal control (Alonso et al., 1986).

3. Northern Blots
Total RNAs were run on a 1% denaturing formaldehyde agarose gel and
electrophoresed in lX MOPS buffer (Sambrook et al., 1989). After electrophoresis, the
gels were soaked for 30 minutes in 50 mM NaOH, rinsed in DEPC-treated water,
neutralized two times for 15 minutes each in 0.1 M Tris-HCl, and blotted to Duralon
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nylon membranes overnight in 20X SSC. After the transfer was complete, the blots
were dried under vacuum at 80°C for two hours, and UV crosslinked at 250
mjoules/mm 2 in a Stratalinker (Stratagene, LaJolla, CA) before prehybridization.

4. RACE
5' RACE was performed using the Clontech SMART™ RACE Kit (Clontech,
Inc.; Palo Alto, CA) according to the manufacturer's

instructions.

RACE was

performed on first strand cDNAs generated from both poly (At RNAs and total RNAs
from brain using both standard and touchdown PCR programs. Primers for the reaction
were ORN 645 and ORN772, used with the universal primer and nested universal
primer supplied with the RACE kit (Table VII-I).

5. MTC Panels
The mouse MTC (multiple tissue cDNA) panel (Clonetech, Inc.; Palo Alto, CA)
was used to analyze, by PCR, expression of the candidate genes in different mouse
tissues.

This panel includes cDNAs from heart, brain, spleen, lung, liver, skeletal

muscle, kidney, testis, and four different embryo stages (7-, 11-, 15-, and 17-day). The

Prmt3 PCRs utilized primers ORN 646 and 648, which amplify a 586 hp fragment from
the 3' end of the transcript. The Tip30/Cc3 PCRs utilized primers ORN 663 and 664,
which amplify a 1060 hp fragment covering the entire coding sequence of the transcript.
Actin-specific primers (ORN 559/560) were m~ed to amplify a 520 hp fragment of

/3-

actin as an internal control (Alonso et al., 1986). For PCR, the conditions were 94° for
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5 min, followed by 30 cycles of 94° for 30 sec, 1 min at the appropriate annealing
temperature (60°C for ORN 663/664, 52°C for ORN 559/560, and at 62°C for ORN
646/648), and 72° for 3 min., then a final five minute extension at 72°C. Products were
analyzed on a 1% agarose gel with ethidium bromide staining (Sambrook et al., 1989).

6. Cloning and Sequencing RT-PCR Products
The PCR products obtained were cloned using the pGEMT-Easy II cloning kit
(Promega Corporation, Madison, WI), following the manufacturer's instructions, and
analyzed by fluorescent sequencing with the Big Dye Terminator Kit (PE Biosystems,
Foster City, CA).

The products were run on an ABI377 DNA sequencer and the

sequence analyzed using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) to verify the
identity of the cloned products.

7. Assembling cDNA Sequences
Individual sequencing runs from the RT-PCR products were assembled into
contigs representing the entire cDNAs using the Sequencher 3.1 software (Gene Codes
Corp., Ann Arbor, Ml).

8. Mutation Screening by Temperature-Gradient
Capillary Electrophoresis
RT-PCR amplified fragments of the Prmt3 cDNA from the control (BJR) and
the two mutant strains (723SJ and 1060SJ) were analyzed for mutations using
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temperature-gradient capillary electrophoresis (TGCE) (Gao and Yeung, 2000). Six
overlapping fragments were analyzed, ranging in length from 204 bp to 530 bp (Figure
VIl-2). The analysis was performed by SpectruMedix Corporation (State College, PA),
in collaboration with Cymbeline T. Culiat of ORNL.

9. Genomic Southern Blotting
Genomic DNAs from 723SJ and 1060SJ psrt mutants and the BJR control were
digested overnight with BstXI., EcoRI, Pstl, and Taql (Gibco BRL Life Technologies,
Rockville, MD) using the following reaction cocktail: 1Oµg of miniprep DNA, 4 µL of
10 X buffer (React2 for with Pstl and Taql, and React3 for BstXI. and EcoRI), 2 µL of
enzyme, and sterile water to make a total volume of 41 µL.

Digestions occurred

overnight at 37°C except those using Taql, which were digested at 65°C. Digested
DNAs were loaded on a 0.8% agarose gel which was run in IX TAE and Southern
blotted using standard protocols (Sambrook et al., 1989).

RESULTS
1. Tip30/Cc3 cDNA Sequence
The Tip30/Cc3 cDNA was amplified using primers ORN 663 and ORN 664,
which amplify a 1060 bp fragment that includes the entire coding sequence of the
Tip30/Cc3 cDNA. Three sets of primers were also used to amplify smaller, overlapping
segments of the cDNA: ORN 663 and ORN 728, which amplify a 615 bp segment in
the 5' end of the cDNA; ORN 664 and ORN 727, which amplify a 464 bp segment in
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the 3' end of the cDNA; and ORN 723 and ORN 726, which amplify a 560 hp segment
in the middle of the cDNA that overlaps the other two segments (Figure VII-3).
The consensus sequence was determined by combining all sequencing data,
including data from both the cloned RT-PCR fragments and from the direct sequencing
of RT-PCR products. No point mutations or other discrepancies in the sequence were
found between the control (BJR) strain and the two mutant strains (723SJ and 1060SJ).

2. Tip30/Cc3 Expression Analysis
Primers ORN 663 and ORN 664 were used to look for expression in tissues
from the Mouse MTC panel. A single 1060 hp fragment was detected for all twelve
cDNAs tested (Figure VII-4), indicating that Tip30/Cc3 is ubiquitously expressed in
mouse adult and embryonic tissues.

3. Prmt3 cDNA Sequence
The Prmt3 cDNA was amplified from the two mutant strains and the control
using two sets of primers that amplify overlapping segments of the cDNA: ORN 646
and ORN 648, which amplifies a 586 hp segment in the 3' end of the cDNA that
includes the stop codon and part of the 3' UTR; and ORN 644 and ORN 647, which
amplify a 685 hp segment in the middle of the cDNA that overlaps the other two
segments (Figure VII-5). No amplification product could be obtained from the 723SJ
psrt cDNA using ORN 645 and ORN 704, which amplify a 569 hp segment in the 5'

end of the cDNA that includes the start codon and a short segment of the 5' untranslated
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region (UTR). There was, however, an amplification product from the 1060SJ mutant
and the BJR control cDNAs.
When visualized on an ethidium bromide stained agarose gel, the ORN 644/647
product amplified from 1060SJ mutants appears to be a single product; however, during
the process of cloning and sequencing, a single clone was isolated that carries an
alternatively spliced insert. This anomalous clone is missing hp 844 to 1063, which
corresponds to exons nine and ten.

Therefore, although this transcript is in low

abundance, at least one alternatively spliced transcript exists for the Prmt3 gene in the
1060SJ animals.
The Prmt3 consensus sequence was determined by combining all sequencing
data, including data from both the cloned RT-PCR fragments as well as from the direct
sequencing of RT-PCR products. No point mutations or other discrepancies in the
sequence were found between the control (BJR) strain and the two mutant strains
(723SJ and 1060SJ).

4. 5' RACE
RACE was utilized in an attempt to amplify the 5' end of the 723SJ Prmt3
cDNA, which could not be amplified by standard RT-PCR. The RACE controls were
successfully amplified; however, repeated attempts at amplification of the 723SJ cDNA
using both total RNAs and poly (At RNAs were unsuccessful. These results suggest
the presence of a possible genomic rearrangement or deletion in the 723SJ Prmt3 allele.
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5. Prmt3 Expression Analysis
Primers ORN 646 and ORN 648 were used to look for expression in tissues
from the Mouse MTC panel. A 586 bp fragment was detected for all twelve cDNAs
tested, and a second, larger fragment was also detected in skeletal muscle and possibly
in heart (Figure VII-6). This indicates that Prmt3 is ubiquitously expressed in mouse
adult and embryonic tissues, and that at least one larger, alternatively spliced transcript
is present in skeletal muscle and heart.
Northern blot analysis of brain total RNA probed with a Prmt3 EST (Genbank
Accession #ai 156519) indicates that the Prmt3 transcript is approximately 2.4-kb,
which agrees with the size previously reported for rat brain {Tang et al., 1998). The
723SJ psrt transcript appears to be slightly shorter than the 1060SJ psrt transcript and
the controls (Figure VII-7). However, this difference is slight, at best, and has not been
quantified.

6. Detection of Genomic Rearrangement or Deletion
The genomic Southern blot of DNAs from the control strain (BJR) and the two
mutant strains (723SJ and 1060SJ) was probed with RT 645/704, a RT-PCR product
from the 5' end of the Prmt3 cDNA transcript. The enzymes used to digest the genomic
DNA were chosen because the genomic sequence (obtained from the BAC containing
the Prmt3 and Tip30/Cc3 genes, B179d14) indicates the presence of restriction sites for
each of the enzymes within the first 20-kb of the Prmt3 gene and the 5-kb of genomic
sequence directly upstream of the gene. In addition, the restriction map of all four
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enzymes shows an abundance of fragments ranging from 0.3-kb to 6-kb, which could be
detected on a Southern blot (Table VII-8). If either a genomic rearrangement or deletion
were present in one of the mutant strains, then the size of the band(s) might be altered
relative to the other strains. The autoradiograph of the probed blot, however, showed
identical bands for the three DNAs, each digested with four different enzymes. This
indicates that, for the four enzymes used, no deletion or rearrangement is detected
(Figure VII-9).

7. Prmt3 TGCE Mutation Analysis
A TGCE analysis is performed by mixing the amplified cDNA from a
homozygous (or hemizygous) mutant with that from the control animal. The samples
are then denatured and allowed to reanneal. If both the mutant and control strands are
identical, then a homoduplex is formed and the electropherogram shows a single,
smooth peak.

However, if mutations are present, including single nucleotide

polymorphisms (SNPs), then both heteroduplexes and homoduplexes will form when
the samples reanneal.
electrophoretic

Since heteroduplexes and homoduplexes have different

mobilities

m

the

electrophoresis

matrix

[in

this

case,

a

poly(vinylpyrrolidone) solution], the shape of the resulting electropherogram will no
longer be a single, smooth peak. Rather, it can range from a single peak with a
"shoulder"

to a multiplet of up to four individual peaks representing two

complementing homoduplexes and both possible heteroduplexes.

88

The TGCE analysis performed by the SpectruMedix Corporation indicates that
mutations are present in both of the mutant strains. Heteroduplex formation occurred in
the 1060SJ cDNA amplified with ORN 648/676, which is from the 3' end of the cDNA
(Figures VII-10 and VII-11). The overlapping segment, ORN 646/677, does not form
heteroduplexes; therefore, there appears to be a mutation somewhere in the 162 bp of
the fragment that does not overlap with ORN 646/677. The heteroduplex was detected
in both of the two independently generated cDNAs from 1060SJ mutants that were
analyzed.
In addition, heteroduplex formation was also detected in the 723SJ cDNA in two
overlapping segments, ORN 646/677 and ORN 648/676 (Figures VII-10 and VII-11).
These two segments represent the 3' end of the cDNA; however, since both segments
form heteroduplexes, the mutation is most probably located in the 89 bp that form the
overlap between the two segments. The heteroduplex was detected in a single 723SJ
cDNA (rather than in both cDNAs) because one of the two submitted samples failed to
produce a signal. The single 723SJ cDNA did, however, show heteroduplex formation
with both of the control samples.

DISCUSSION
The Tip30/Cc3 gene appears to be intact and the sequence is identical in the
control strain and in psrt homozygotes animals from the two mutant strains. Although a
sequence analysis using a cDNA-based primer set indicates that the Prmt3 cDNA
sequence is unchanged between the control and the two mutant strains, there is evidence
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to suggest that the Prmt3 gene is altered in the mutants. Northern blot analysis suggests
a possibly shortened transcript in the 723SJ mutants, and the 5' end of the 723SJ
transcript could not be amplified, either by standard RT-PCR or by RACE. A genomic
rearrangement or deletion could be the cause of the problem; however, Southern blot
data failed to verify a genomic alteration.

TGCE data strongly indicate that mutations

are present in the Prmt3 transcripts from each of the two mutant strains, both in the 3'
end of the transcripts, with the 723SJ mutation occurring in a position more 5' than the
1060SJ mutation.

Additional sequence analysis will be required to verify these

mutations as well as to ascertain conclusively if there is an aberration in the 5' end of
the 723SJ transcript.
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CHAPTER VIII
ANALYSIS OF METHYLARGININE IN THE MYELIN BASIC PROTEIN
OF psrt MUTANT ANIMALS

ABSTRACT
To assess the methylation status of the arginine-107 (R-107) residue of the
myelin basic protein (MBP), MBP was extracted from psrt mutant and non-mutant
mouse brains.

The MBP was hydrolyzed and the amino acids derivatized with N-

methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide

{MTBSTFA) to produce tert-

butyldimethylsilyl (t-BDMS) derivatives. The derivatized amino acids were analyzed
by gas chromatography with mass spectrometric detection (GC/MS) to determine the
methylation status of the arginine residues in MBP.

The hydrolysate from the control

animals contained the expected methylarginine residue at quantifiable levels, while the
hydrolysate from the psrt mutants contained no detectable methylarginine.

INTRODUCTION
One of the candidate genes for the psrt phenotype is a protein arginine Nmethyltransferase, Prmt3, whose specific in vivo substrate is unknown. Although there
are several proteins known to contain methylarginine residues, the myelin basic protein
(MBP) is the only known methylarginine (Me-R)-containing protein that is involved in
neurological function. MBP contains a single Me-R residue, arginine-107 (R-107), that
can be either monomethylated or symmetrically dimethylated.
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If Prmt3 is the gene responsible for psrt, then the mutants will exhibit abnormal

protein arginine methylation. Furthermore, if MBP is the substrate for Prmt3, then
abnormal methylation patterns would be present in the MBP isolated from the mutants.
To investigate this possibility, MBP from the brains of the psrt mutants and their nonpsrt littermate controls were analyzed for the presence of methylargine (Me-R).

MATERIALS AND METHODS
1. Isolation ofMBP

MBP was extracted from two groups of 14 day old brains: seven pooled psrt
brains, totaling 2.08 grams, and seven pooled control brains, totaling 2.61 grams. The
pooled mutant sample class included five 1060SJ psrt homozygotes (genotype ru2 mp I
ru2 mp)

and two hemizygotes (genotype ru2 mp I Dj[ru2-p]); the pooled 1060SJ

control animals included five wild-type animals (genotype ru2 + + I + + p) and two
non-carrier ru2 animals (genotype ru2 + + I ru2 + +). MBP was isolated using a
variation of the technique developed by Maatta et al. (1997). Briefly, the brains are
homogenized in chloroform (99.9%, spectrophotometric grade, ACS reagent; Burdick
and Jackson Laboratories, Inc., Muskegon, Ml) and the homogenate is centrifuged to
isolate the MBP-containing organic phase from the pellet and the aqueous phase. The
pellet is re-homogenized in chloroform and the process is repeated. The organic phases
are combined, washed in water ('Baker Analyzed'® HPLC reagent; J.T. Baker,
Phillipsburg, NJ) and centrifuged again.

The MBP-containing organic phase is

removed, mixed with ('Baker Analyzed'® HPLC reagent) methanol (J.T. Baker,
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Phillipsburg, NJ) and vortexed. Acidified water (containing HCl) is added, and the
mixture is vortexed again. At this stage, the MBP is dissolved in the acidic aqueous
phase, which is removed and dried in a rotary evaporator.

2. Hydrolysis and Derivatization of MBP
The dehydrated MBP, which is a filmy residue in the bottom of the round
bottom flask, is dissolved in 500 µL of 6M constant-boiling HCL (Pierce Chemical Co.,
Rockford, IL) and transferred to a hydrolysis tube.

The hydrolysis is carried out

overnight at 110°C to 120°C under vacuum. The hydrolysate is dried by warming to
55°C under a stream of nitrogen, then derivatized at 80°C for one hour using 30 µL of
MTBSTF A + 1% TBDMCS (tert-butyldimethylchlorosilane, a catalyst) (Pierce
Chemical Co., Rockford, IL) and 30 µL of pyridine (99.8%, anhydrous; Sigma, Inc., St.
Louis, MO).

3. GC/MS Analysis
Samples were analyzed using a Hewlett-Packard model 5890 gas chromatograph
with a HP-5MS capillary column (30m x 0.25mm i.d.; 0.25 µm film thickness). The
detector was a model 5989A quadrupole mass spectrometer operating in electron impact
ionization mode. The ion source was maintained at 70 eV and 200°C. The carrier gas
was helium and the column head pressure was 7 psi. The injector temperature was
250°C and the temperature program was as follows: 60°C for two minutes, then ramp
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at 5°C per minute for 44 minutes to 280°C and hold for five minutes. The total run lasts
51 minutes.
4. Amino Acid Standards
Glycine (gly), lysine (lys), methylarginine (me-R), and tyrosine (tyr) (Sigma, Inc.,
St. Louis,

MO)

were individually dissolved

in methanol

(me-R),

(1:1, v:v)

methanol:water (gly, lys, and phe) and pH 2 water (tyr). Aliquots from these solutions
were combined and dried under nitrogen at 55°C then derivatized as described above to
produce solutions containing 50, 100,200, and 300 ng/µL of each amino acid. One µL
of each of these combined standards was injected and analyzed using capillary GC/MS
as described above. The peak areas from the chromatographs were utilized to produce a
calibration curve for each amino acid, which was used to quantitate the amount of these
amino acids present in the MBP samples from the mutant and control animals.

RESULTS
1. Calibration Curves for Amino Acid Standards
The calibration curves for the four amino acid standards (glycine, lysine,
methylarginine, and tyrosine) are all roughly linear over the concentration ranges tested
(50 ng to 300 ng injected) (Figure Vill-1). Extrapolation from the curves for each of
the standards allows for quantitation of the standards in the samples (Table Vlli-2).
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2. Amino Acid Analysis of Chromatographs
of Mutant and Non-Mutant Mice
The total ion chromatograph of the derivatized hydrolysate of the control mice
shows a methylarginine peak area of 3,523,593 which corresponds to approximately
100 ng of methylarginine. The total ion chromatograph of psrt mutant brains does not
have a methylarginine peak, indicating that the level of Me-R present is below the
detection limit (Table VIII-2).
The chromatographs of the derivatized MBP hydrolysate from the psrt mutant
animals and the non-mutant controls are similar, with many peaks in common. They
are not, however, exactly alike. The peaks on the chromatograph from the mutants tend
to be smaller than those from the controls, and there are peaks from the control
chromatograph that are missing in the mutants. The Me-R peak is clearly seen in the
control chromatograph, but is missing in the psrt chromatograph (Figures VIII-3 and
VIII-4).

DISCUSSION
The GC/MS analysis indicates that there are no detectable levels of Me-R
present in the MBP of the pooled psrt mutant brains. This could be due to several
different reasons. Although the same number of brains were pooled for the psrt and
control samples, the psrt brains are smaller; therefore, the total mass of mutant brains is
20.3% less (2.08 grams) than the total mass of the control brains (2.61 grams). In
addition, the psrt mutants are runted and appear to be developmentally delayed. Even

95

though MBP mRNA and protein expression have been occurring since before day eight
in normal mice, it is possible that there is a delay in this process in the mutants, which
would mean that not as much MBP and, therefore, Me-R is present in the mutants as is
present in age-matched controls. The quantity of material present in the mutant MBP
hydrolysate as compared to the control MBP hydrolysate (as determined by comparing
peak areas of tyrosine and lysine to the calibration curves) tends to support this notion
{Table VII-2). The fact that there was a visible film on the flasks at the end of the MBP
isolation and the presence of quantifiable amounts of amino acids in the mutant
chromatographs,

however, implies that protein was indeed present.

This assay is

designed to isolate relatively pure MBP and the pH is adjusted to below two in order to
insure that other basic proteins, such as histones, will precipitate out of solution, leaving
only the MBP in the final acidic aqueous phase (Maatta et al., 1997). Therefore, MBP
appears to be present in the mutant brains, even though Me-R was not detected.
This evidence suggests that a defect in protein arginine methylation is present in
the mutants; however, it is not conclusive. There was less MBP present in the mutants
than in the control brains, and the quantity of Me-R detected in the control brains was
nearing the detection limit for the method. Since multiple brains are required for this
assay and only a few mutant brains were available for analysis, a single trial was
conducted using only one of the two mutant strains (1060SJ).

A more complete

analysis involving multiple samples from both mutant strains is needed to conclusively
determine if the biochemical defect inpsrt mutants affects the methylation of the R-107
residue of MBP.
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CHAPTER IX
EVALUATION OF CANDIDATE GENES

INTRODUCTION

A positional cloning strategy, consisting of physical mappmg followed by
shotgun sequencing of genomic clones, was employed to identify two genes (Tip30/Cc3
and Prmt3) mapping into the same p-region deletion interval as the psrt phenotype. In
addition, a positional candidate strategy was used to identify a third gene, Glyt2,
mappmg into the homologous region of the human genome.

What follows 1s a

discussion of each of the three genes and an assessment of their candidacy.

DISCUSSION

1. Assessment of the Candidacy of Tip30/Cc3
The Tip30/Cc3 gene was identified as a candidate gene because it maps into the
same p-region deletion interval as the psrt phenotype. It was discovered through
sequence analysis of a BAC clone that is part of the physical map of the region. Since
Tip30/Cc3 is involved in transcription, a mutation in this gene would affect the
transcriptional machinery and/or processes in the mutant animals.

A ubiquitously

expressed, transcription-related gene such as Tip30/Cc3 might be responsible for a
runting phenotype, especially since Cc3 is involved in promoting apoptosis; however,
Tip30/Cc3 has not been linked to neurological function.
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The entire coding sequence of the Tip30/Cc3 cDNA was sequenced in the
control (BJR) and both mutant strains, and no mutations were found. Based on this
information and the inability to link the function of the Tip30/Cc3 gene product to a
neurological phenotype, it is not considered a strong/viable candidate for the psrt
phenotype.

2. Assessment of the Candidacy of GlyT2
The human genome sequencing databases were searched for candidate genes mapping
within 1 lp14-p15, the region homologous to the psrt region ofMmu 7. The aim was to
find genes associated with phenotypes similar to psrt, namely runting, seizures, and
prenatal or juvenile lethality. Although no known human disease genes were found to
map within the interval, the glycine transporter type 2 (GLYT2) gene was identified as a
candidate because of its involvement in neurological function.
There are several reasons why Glyt2 could be the gene responsible for the psrt
phenotype.

A mutation in Glyt2 could alter glycine transport in the mutant animals,

which would lead to nervous system dysfunction and neural degeneration.

The

dysregulation of neurotransmitter transport alters the amount of neurotransmitter
present in the cell, in both the cytoplasm and in the synaptic vesicles. This has been
shown to alter synaptic strength (Liu and Edwards, 1997; Pothos et al., 2000).
Neurotransmitter toxicity, resulting from the accumulation of neurotransmitter in the
cell, can lead to neuropathological conditions.

Dopamine toxicity, for example, has

been associated with Parkinson's disease (Liu and Edwards, 1997), and elevated
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extracellular concentrations of glutamate have been associated with a number of
neurodegenerative diseases, including ALS (Lou Gehrig's disease), Huntington's
disease, and Alzheimer's disease (Gegelashvili and Schousboe, 1997).
The seizure phenotype seen in psrt animals is compatible with a loss of
inhibitory neurotransmission. Their limbs are stiff and extended for the duration of the
seizure, not unlike the effects of strychnine poisoning, which causes convulsions and
muscle contractions and is often fatal (Alberts et al., 1996). Strychnine is a glycine
antagonist, meaning that it competes with glycine at the glycinergic synapses and
interferes with inhibitory neurotransmission. If the psrt phenotype were caused by
mutations in Glyt2, then glycine transport would be dysfunctional. Altered glycine
transport would cause the accumulation of glycine at the postsynaptic membrane, which
could have a neurotoxic effect on the nervous system and lead to the death of the
animal. The affect of the accumulation of glycine at the postsynaptic membrane is
unknown; however, it is likely that excess glycine would cause an increase in inhibitory
neurotransmission, which is the opposite effect to the observed phenotype.
In the mouse, CNS and PNS myelination occur after birth (Raine, 1984a). The

onset of seizures in the psrt mutants occurs between seven and ten days of age, just as
the nervous systems are developing. Glycinergic motoneurons are associated with
rhythmic movements, such as locomotion and respiration. These movements involve
repeating cycles of precisely coordinated excitation and inhibition (Rekling et al.,
2000). Therefore, if glycine transport were dysfunctional in the psrt mutants, there
would be an effect on rhythmic movements, and the visible effects might increase as the
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nervous system matures and rhythmic movements increase. This appears to be the case
with psrt mutants, since the onset of seizure activity occurs at about seven to ten days
after birth.
The psrt phenotype could be caused by a mutation in Glyt2. Such a mutation
would affect glycine transport, and altered glycine transport would severely affect
nervous system function. The seizures in the psrt mutants are first observed during the
time that the nervous systems are developing, and death occurs within a week of the
onset of seizures. Therefore, there is a temporal correlation between the observed psrt
seizure phenotype and the function of the Glyt2 protein. Since Glyt2 was discovered
near the end of this project when the molecular work was nearly complete, no molecular
data are available for it. Molecular expression data are necessary to thoroughly evaluate
the candidacy of glyt2; without them, no conclusions can be drawn for the candidacy of

g/yt2. Therefore, although glyt2 appears to be a viable candidate for the psrt phenotype,
a full assessment of its candidacy must, by necessity, await molecular expression data
and sequencing.

3. Assessment of the Candidacy of Prmt3
In order to assess the candidacy of Prmt3 as the gene responsible for the psrt
phenotype, it is necessary to examine the link between protein arginine methylation and
neurological function.

The only molecularly characterized mammalian mutation

involving a protein arginine methyltransferase gene involves the mouse Prmtl gene.
Unfortunately, Prmtl null homozygotes die at around day E6.5; therefore, it is
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impossible to determine the effect(s) of Prmtl on the developing nervous system.
There is, however, one other well-known link between protein arginine methylation and
nervous system function, and it involves the myelin basic protein (MBP).
Myelin is a membrane architecture found within the central (CNS) and
peripheral (PNS) nervous systems.

Its function is to insulate the axon, thereby

increasing the velocity of the nerve impulse (Kim et al., 1997b; Raine, 1984a; Alberts et
al., 1996). Myelin contains about 80% lipid and 20% protein, and MBP comprises

approximately 30% of the total CNS protein (Lees and Brostoff, 1984).
MBP is a peripheral membrane protein localized to the major dense line regions
of compact CNS and PNS myelin. It is located on the cytoplasmic side of the
phospholipid bilayer of either the oligodendrocyte in the CNS or the Schwann cell in
the PNS (Raine, 1984a). During CNS development, certain hnRNPs bind to and
transport MBP mRNA from the nucleus to the distal ends of the oligodendrocyte
processes.

Once there, the MBP mRNA is anchored to the myelin membrane and

translated into protein (Hoek et al., 1998).

As myelinogenesis progresses, the

cytoplasm is extruded and the membranes begin to wrap spirally until multiple layers of
membrane and protein surround each axon (Omlin et al., 1982; Raine, 1984a). A
similar process occurs in the Schwann cell in the PNS, except that MBP comprises a
smaller percentage of the total protein in PNS myelin (Lees and Brostoff, 1984; Raine,
1984a).
MBP

undergoes several posttranslational modifications;

however, the

methylation of the arginine-107 (R-107) residue appears to be a nearly universal
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modification. Only one exception, carp, has ever been noted (Kies et al., 1972; Deibler
and Martenson, 1973; Young et al., 1987). The methylation of the R-107 residue is
critical to the function of MBP within the myelin membrane, affecting the ability of the
protein to bind to the myelin membrane.

This methylation is also involved in

maintaining the integrity of the myelin sheath (Kim et al., 1997b; Zand et al., 1998;
Boggs et al., 1999), and has been implicated in multiple sclerosis (MS), possibly as the
autoantigen responsible for the disease (Moscarello et al., 1994). Irrespective of the
cause of the disease, however, the MBP from MS patients contains less methylarginine
than would be expected (Moscarello et al., 1994; Rawal et al., 1995a; Kim et al.,
1997b). Therefore, there appears to be a correlation between MBP methylation and the
demyelination that occurs in MS, which supports the assertion that a defect in MBP
methylation could be responsible for the neurological phenotype seen in psrt mutants.
There are at least eight known hereditary diseases that cause a dysmyelination
phenotype

m

humans

(metachromatic

leukodystrophy,

Krabbe's

disease,

adrenoleukodystrophy, Refsum's disease, Pelizaeus-Merzbacher disease, Alexander's
disease, Canavan's disease, and phenylketonurea). However, none of these diseases is
known to directly involve MBP (Raine, 1984b). In the mouse, there are several wellcharacterized mutants with a dysmyelination phenotype.

These include jimpy (jp),

quaking (qk), murine muscular dystrophy (dy), Trembler (Tr), shiverer (shi) and myelin
deficient (shim1d) (Raine, 1984b). Although MBP levels are lowered in some of these
mutants (Bourre et al., 1980; Jacque et al., 1983), only two of them, shi and shimldhave
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been shown to be mutations in the MBP gene itself (Roach et al., 1983; Popko et al.,
1987).
The shiverer (shi) mutation is an autosomal recessive mutation that maps to
Mmu 18 (Barbarese et al., 1983; Sidman et al., 1985; Raine, 1984b). It is a lethal
mutation, characterized by seizures, with death occurring between two and five months
of age (Readhead et al., 1987). Shiverer mice exhibit severe dysmyelination. The CNS
in these mice is characterized by grossly disorganized myelin sheaths (Rosenbluth,
1980a); however, only subtle changes are detectable in the PNS myelin (Kirschner and
Ganser, 1980; Rosenbluth, 1980b). Brains of shi mice contain virtually no MBP mRNA
or protein (Roach et al., 1983). The myelin deficient (shimld) mutation is allelic to shi,
with shimld animals exhibiting a similar, but less severe phenotype. The CNS of shimld
mice is hypomyelinated, and death occurs at a later time, between five and nine months
of age. Unlike shi mice, however, shr 1d homozygotes express reduced, but detectable,
levels of MBP mRNA and protein (Popko et al., 1987). Molecular analysis indicates
that the shi mutation involves a nearly complete deletion of the MBP gene (Roach et al.,
1983). The shimtd mutation, on the other hand, stems from the presence of multiple,
linked copies of the MBP gene, with some of these copies containing a rearrangement,
but at least one intact MBP gene (Popko et al., 1987).
If the function of the PRMT3 protein is to methylate the R-107 residue ofMBP,
then it becomes necessary to address the question of why the phenotype of psrt animals
is so much more severe than the phenotypes of either shi or shimtd mice. Since the shi
allele is a deletion of MBP and the shi phenotype is characterized by the near absence of
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MBP, shi is considered to be a null mutation; yet the animals live between two and five
months. The shimtd mutation is hypomorphic, with very low levels of MBP detected in
the mutants, and these animals live between five and nine months. Conversely, psrt
animals, which presumably have a wild-type MBP gene but may lack the ability to
properly methylate the MBP protein, live only 15 to 18 days after birth.
Although this evidence appears at first to be to the contrary, it does not preclude
the possibility that the function of the PRMT3 protein is to methylate the MBP. The shi
mutation is carried on a Swiss Vancouver (SWV) background (Bird et al., 1978; Hogan
and Greenfield, 1984), while psrt is on a BJR background. The genetic background of
the shi animals is different from the psrt animals, and it has been shown that genetic
background can have a dramatic effect on phenotype. For instance, mice homozygous
for a transgenically inserted null allele of the epidermal growth factor receptor (Efgr)
display a variety of phenotypes, depending on the genetic background of the transgenic
animal. These phenotypes are all lethal; however, death can occur anytime from periimplantation (on a CF-1 background) to mid gestation (on a 129/Sv background) to 20
days after birth (on a 129/Sv x C57BL/6 x MFl background) (Sibilia and Wagner,
1995; Threadgill et al., 1995). Therefore, mutations affecting the same biochemical
processes (i.e. myelination) in different strains of mice (i.e. SWV and BJR) can have
widely differing phenotypes due to the differences in genetic background.
Since the psrt phenotype includes runting in addition to the neurological
(seizure) phenotype, it is also possible that PRMT3 may have more than one in vivo
substrate and, consequently, a mutation in Prmt3 could cause more than one effect.
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This idea of multiple substrates is supported by the fact that the MBP gene is expressed
only in the nervous system, in oligodendrocytes and Schwann cells (Raine, 1984a),
while Prmt3 is ubiquitously expressed.

Therefore, the differences in phenotype

between psrt and shi animals could be caused by either one or both of two things: ( 1)
the mutations are on different genetic backgrounds, and (2) there is more than one
substrate for PRMT3, which could amplify the pheyotypic effect of a mutation in the
gene.
PRMT3, unlike other known PRMTs, contains a zinc-finger motif, and it has
been suggested that this specific part of the protein is responsible, at least in part, for its
substrate specificity (Frankel and Clarke, 2000). Zinc fingers are associated with ligand
binding, most commonly with protein-DNA binding, but also with protein-RNA and
protein-protein interactions (Mackay and Crossley, 1998). Since the MBP mRNA is
bound to an hnRNP, it seems reasonable that the enzyme responsible for methylating
the MBP might be capable of binding either to the MBP mRNA, the hnRNP that carries
it to its final destination, or the MBP itself. Furthermore, immunolocalization studies
indicate that PRMT3 is primarily cytoplasmic (Tang et al., 1998). Once transcription is
complete (in the nucleus), the nascent MBP mRNA binds to an hnRNP and is
transported from the nucleus to the end of the oligodendrocyte process, where it is
anchored to the membrane and translated into protein (Hoek et al., 1998).

It is

reasonable to expect that any protein responsible for modifying MBP would be
localized in the cytoplasm, since the MBP mRNA spends most of its lifetime in the
cytoplasm and the MBP protein is entirely cytosolic.

Therefore, the ligand-binding
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capabilities and the intracellular location of the PRMT3 protein are consistent with
those of an enzyme that could modify MBP.
Earlier

studies have suggested that a single methyltransferase

could be

responsible for all three types of methylarginine; however, it was later determined that
the Type I activity (producing Me 2Arg and Me 2(asym)Arg) and the Type II activity
(producing Me 2Arg and Me2(sym)Arg) could be separated (Lee et al., 1977). Despite
the isolation of specific methyltransferase activities and numerous efforts to purify the
proteins responsible, all attempts to purify to homogeneity and sequence the proteins
responsible for these activities have failed (Lin et al., 1996; Gary and Clarke, 1998;
Tang et al., 2000). It is interesting to note that the enzyme responsible for the Type I
activity (producing solely MeArg and Me 2(asym)Arg) is inhibited by MBP, a substrate
for the Type II activity (Park et al., 1989). Competitive inhibition of an enzyme by its
product is a common phenomenon; however, MBP from mature myelin contains only
MeArg and Me 2(sym)Arg, making it a product of the Type II, and not the Type I PRMT
enzyme.

This suggests that the criteria for classifying PRMT enzymes may not be

absolute, and that MBP could be methylated by an enzyme that has been classified as
Type I.
Although a GST-PRMT3 fusion protein has been shown to exhibit Type I
PRMT activity, meaning that it produces solely MeArg and Me 2(asym)Arg residues in
an artificial substrate (Tang et al., 1998; Zhang et al., 2000), there is evidence
suggesting that native PRMTs and their GST fusion proteins may have different
properties (Frankel and Clarke, 2000). Since the natural substrate for PRMT3 has not
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been identified (Smith et al., 1999) and the native protein has not yet been isolated and
purified, it is impossible to know for certain how PRMT3 functions in vivo. Therefore,
it is possible that the native PRMT3 protein, unlike the fusion protein containing only a
part of the total enzyme, might exhibit some Type II PRMT activity in vivo.
Along these same lines, it has been assumed that the PRMT enzyme {Type I or
Type II) is solely responsible for determining the methylation state of its substrate.
There is evidence, however, to suggest that the context of, or the environment
surrounding, an arginine residue can also affect its methylation state (Rawal et al.,
1995a; Brahms et al., 2000).

In order for Sm proteins Dl and D3 to be properly

(symmetrically) dimethylated, they must first be assembled into their native heterooligomeric complex.

Unassembled Dl subunits are improperly (asymmetrically)

dimethylated (Brahms et al., 2000).

It has also been shown that immature myelin

contains a higher abundance of exon-2-containing MBP isoforms (Kruger et al., 1999).
These proteins would vary in their N-terminal residues, which are a part of the NAR (Nterminal acidic region) containing the methylated R-107 residue. Since the methylation
status of MBP changes as the myelin matures (Rawal et al., 1995a), it is possible that
the change in the environment near the R-107 residue is affecting the methylation status
of R-107. Furthermore, it has been shown that MBP undergoes a steric transformation
upon binding to lipids, with an increase in secondary structure of the protein (Lees and
Brostoff, 1984). A change in environment could result either from the presence of
different MBP isoforms at different developmental stages or through steric changes in
the protein resulting from the association of MBP with other proteins or membrane
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lipids. This opens the possibility that the enzyme responsible for modifying the MBP
might act as a Type I enzyme under certain circumstances but, when the context of the
R-107 changes, can act as a Type II enzyme. Therefore, despite reports that GSTPRMT3 exhibits no Type II activity, until the native protein and its substrate can be
studied in vivo, it is at least a possibility that MBP could be an in vivo substrate of
native PRMT3.
Perhaps the most compelling evidence supporting the candidacy of Prmt3 in the
psrt phenotype is the temporal correlation between myelination, PRMT activity, and the
psrt phenotype. In mice exhibiting the psrt phenotype, the onset of seizures occurs

approximately 7-10 days after birth, with seizure activity increasing in duration and
intensity until the animal eventually dies, typically between 15 and 18 days after birth.
In the mouse, MBP mRNA expression is first detectable by northern blot at around 7

days (Mathisen et al., 1993; Haas et al., 1995). MBP mRNA expression, MBP protein
synthesis, MBP-specific methylase activity, and myelination occur synchronously,
peaking at 16-18 days after birth (Campagnoni et al., 1978; Carson et al., 1983;
Chanderkar et al., 1986; Rawal et al., 1991). Therefore, the onset of seizure activity in
the psrt animals correlates with the onset of MBP expression and CNS myelination, and
death occurs at the peak of myelinogenesis.
There are several reasons why Prmt3 could be responsible for methylating the
R-107 residue of MBP, a posttranslational modification that is critical to the function of
MBP within the myelin membrane. If the PRMT3 protein is responsible for this
methylation, then a mutation in the Prmt3 gene could cause a lethal neurological
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phenotype such as psrt. Since the in vivo substrates of PRMT3 are unknown, it is also
possible that there are other PRMT3 substrates (such as bFGF) that, when improperly
methylated, could lead to either a runting or a neurological phenotype.

CONCLUSIONS
Of the three genes examined in this work, Prmt3 is the leading candidate for the
cause of the psrt phenotype. The entire coding sequence of the Tip30/Cc3 cDNA was
sequenced for the control and both mutants, and no mutations were found. Based on
this information and the inability to link the function of the Tip30/Cc3 gene product to a
neurological phenotype, it is not considered a strong candidate for the psrt phenotype.
Although Glyt2 does appear to be a viable candidate for a neurological phenotype, it
was discovered only recently; therefore, a thorough assessment of its candidacy,
including a molecular expression analysis, has not been completed.
The most probable assertion, based on the evidence presented, is that Prmt3 is
the gene responsible for the psrt phenotype. Protein arginine methylation has been
linked to neurological function. The methylation of the R-107 residue of MBP is
critical to the function of MBP within the myelin membrane. It has been shown that
myelin is severely affected by either the absence of MBP (as in shi mice) or incorrectly
methylated MBP (as in MS). The cellular localization pattern of the PRMT3 protein is
the same as MBP. Furthermore, there is a temporal correlation between myelination
and the psrt phenotype. Therefore, if the PRMT3 protein is responsible for methylating
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the R-107 residue of MBP, then a mutation in the Prmt3 gene could effect a lethal
neurological phenotype such as psrt.

It is important to emphasize that PRMT3 could be responsible for the psrt
phenotype even if MBP is not an in vivo substrate for the enzyme. Mutations in Prmt3
would lead to the improper methylation of arginine residue(s) in its substrate(s). Since
the in vivo substrates of PRMT3 are unknown, it is possible that other substrates (such
as bFGF) exist that, when improperly methylated, could lead to either a runting or a
neurological phenotype.
The molecular evidence presented in this work suggests that the psrt mutants
have altered Prmt3 alleles. Although sequencing efforts have failed to detect a mutation
in the coding region of the cDNAs from either of the two homozygous mutants,
preliminary data from a mutation screen utilizing temperature-gradient capillary
electrophoresis (TGCE) (SpectruMedix, State College, PA) strongly suggest that a
mutation is present in the 3' end of the transcript from the 1060SJ allele. In addition,
MBP from 14 day old 1060SJ mutants contains no detectable amounts of MeArg, while
MeArg Cc!Jlbe easily seen in age-matched littermate controls. This indicates that there
is a lack ofMBP-specific PRMT activity in the 1060SJ mutants.
The TGCE data also suggest a mutation in the 3' end of the transcript of the
723SJ allele, which has been difficult to characterize molecularly. The S'end of the
723SJ Prmt3 transcript could not be amplified, either by standard RT-PCR or 5' RACE.
Northern blot analysis indicates that the 723SJ transcript may be shorter than the
1060SJ allele and the control; however, this difference is only very slight, at best. This
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suggests that some type of genomic rearrangement or microdeletion may be present in
the 723SJ allele. Unfortunately, an initial attempt to verify an alteration in the 723SJ
allele was unsuccessful.
Molecular and biochemical evidence presented in this work support the assertion
that the psrt animals have an alteration in the Prmt3 transcript. This evidence, together
with the nature of the phenotype, leads to the conclusion that the Prmt3 gene is
responsible for the psrt phenotype.
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CHAPTERX
FUTURE WORK

The findings from this work suggest that Prmt3 is the gene responsible for the
psrt phenotype.

They do not, however, prove this assertion.

In order to prove

unequivocally that Prmt3 is the gene responsible for the psrt phenotype, there are
several experiments that need to be done. First of all, the 5' end of the 723SJ Prmt3
transcript will have to be sequenced. Since RT-PCR and RACE failed to accomplish
this, it will be necessary to sequence from genomic DNA. Even if another Southern
blot (using different restriction enzymes) shows a rearrangement or deletion, sequence
data will be necessary to define the nature of the mutation. It is also important to find
the mutations that the TGCE heteroduplex analysis indicates are present in the 3' ends
of the mutant transcripts. Further sequence analysis, utilizing either genomic DNA or
cDNAs, will be needed. The larger transcripts detected in skeletal muscle and heart
also must be characterized.
In order to prove that the biological function of the Prmt3 gene is to methylate

MBP, an additional Me-R assay must be performed, this time using both mutant strains.
The experiment should be repeated using more brains (and, therefore, more MBP) so
that the level of Me-R detected in the control animals is substantially above the
detection limits for the procedure. And finally, either a gene knock-out from a wild
type animal or a transgenic rescue of a mutant will serve as definitive proof that Prmt3
is the gene responsible for the psrt phenotype in the mouse.
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Figure 11-1. The Limits of the p-Deletion Complex.

Mouse chromosome 7 is

represented by the central horizontal line, with the centromere to the left and the
telomere to the right. Molecular markers are listed directly above the chromosome and
phenotypes that have been mapped but not molecularly characterized are listed directly
below the chromosome. Ldh3, Myodl, Saal, and ru2 are loci that cannot be ordered
relative to the centromere. The heavy, shorter horizontal lines below the chromosome
represent two of the p deletions. p 46DFiOD is the most proximally extending deletion and
p 30PUb is the most distally extending deletion. Their proximal and distal breakpoints,

respectively, define the limits of the p-deletion complex. This figure is adapted from
Dhar MS, Johnson DK (1997) A microsatellite map of the pink-eyed dilution (p)
deletion complex in mouse Chromosome 7. Mamm Genome 8, 143-145.
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Figure 11-2. Mutagenesis Scheme Using the p 46DFiOD Deletion to Select New
Recessive Mutations. The mutagenized chromosome has two morphological markers,
ru2 and p. The mutagenized Gomale animal is crossed to an animal that is homozygous

wild type at both the p and ru2 loci to produce phenotypically wild-type G 1 offspring.
G 1 animals are crossed to animals carrying the p 46DFiOD deletion opposite ru2 (in this
case).

The G2 offspring fall into three classes: wild-type (which represents two

genotypes), the ru2 carrier class, and the ru2 p test class. This figure is adapted from
Rinchik EM, Carpenter DA, Handel MA (1995) Pleiotropy in microdeletion syndromes:
Neurological and spermatogenic abnormalities in mice homozygous for the p 6H deletion
are likely due to dysfunction of a single gene. Proc Natl Acad Sci USA 92, 6394-6398.
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/(7)1RI

ru2

------+-+-----------p46DFiOD
------------------p47DTD
-----------p2MNURf

--------pBOK

Figure 111-1. Mapping the psrt Phenotype by Trans-Complementation Analysis.

There are four p deletions that fail to complement the psrt phenotype:

p 46DFioD,p 47Dm,

p 2MNURf, and p 3RD 3 ooH_ All other deletions complement the phenotype. Therefore, the
psrt

minimal region, which is represented by the large gray rectangle, is defined as the

deletion interval bordered proximally by the proximal breakpoint of p 2MNURJ and
bordered distally by the proximal breakpoints of p 8RlSOM and p 80 \ which cannot be
resolved at this time. At the beginning of this project, the endpoints of the p3RD

3 ooH

deletion had not been well characterized, so this deletion is not included in this map.
Ldh3, Myodl, and Saal are loci that cannot be ordered relative to the centromere. The
white box on the p 8°K deletion indicates that it is a "skipper," or a noncontiguous
deletion that is most likely a complex rearrangement.
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Table IV-1. STSs Used in Physical Mapping.

Description of STS
microsatellite

Method
PCR

How Used
BACDNAs

D7Mit69

microsatellite

PCR

BACDNAs

D7Mit70

microsatellite

PCR

BACDNAs

D7Mit84

microsatellite

PCR

BACDNAs

D7Mitl45

microsatellite

PCR

BACDNAs

D7Mit160

microsatellite

PCR

BACDNAs

D7Mitl93

microsatellite

PCR

BACDNAs

D7Mit229

microsatellite

PCR

BACDNAs

D7Mit230

microsatellite

PCR

RT 591/592

RT-PCR product
(Prmt3)
RT-PCR product
(Prmt3)
BACend
BACend
BACend

PCRand
Hybridization
Hybridization

BACDNAsand
deletion panel DNAs
BAC DNAs and BAC
Southern blots
Deletion panel blots

PCR

B 179d 14/EcoRV /SP6

PCR product (same
as B4514/Pvu/T7)
BACend

Hybridization

B 179d 14/EcoRV /T7

BACend

Hybridization

B36n10/B2A

Single Primer PCR
product
Single Primer PCR
product

Hybridization

Deletion panel blots
and BAC Southern
blots
Deletion panel blots
and BAC Southern
blots
Deletion panel blots

Hybridization

Deletion panel blots

NameofSTS
D7Mit26

RT 595/596
B36n 10/EcoRV /SP6
B36n10/EcoRV/T7
B4514/Pvu/T7

ORN 609/610

B179d14/B1B

Hybridization
Hybridization
Hybridization

BAC Southern blots
BAC Southern blots
Deletion panel blots
and BAC Southern
blots
BACDNAs

157

N

..-1

~

....

~
t-~

e,,;<I
Ip460Fi00
PJOPUb

Figure IV-2.

The p-Deletion Complex with New Microsatellite Markers.

D7Mit230 and D7Mit312, two markers that were mapped as part of this project, are

included on this map. D7Mit230 maps to the same deletion interval as D7Mit193, and
D 7Mit312 maps outside the p-deletion complex. The two most proximally and distally

extending of the p-deletions, p 46DFiOD and p 30 PUb' are shown. This figure is adapted
from Dhar MS, Johnson DK (1997) A microsatellite map of the pink-eyed dilution (p)
deletion complex in mouse Chromosome 7. Mamm Genome 8, 143-145.
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Figure IV-3.

I
i p3RD300H

Defining the Breakpoints of the p 3RDJOOH Deletion.

PCR analysis

indicates that three microsatellite markers map within the p3RD 3ooH deletion: D7Mit193,
D7Mit230, and D7Mit145.

p3RD 3ooH

does not delete five other microsatellites that were

tested: D7Mit26, D7Mit69, D7Mit70, D7Mit84, and D7Mitl 60. These data indicate
that p 3RDJOOH is a noncontiguous deletion (or a "skipper") since it does not delete
D7Mit70.

Previous studies indicate that the p 3RDJOOH deletion encompasses three

molecular markers: p, Gas2, and D7Hl 5F37Sl (Johnson et al., 1995). This places the
proximal breakpoint of

p3RD 3ooH

between D7Mit26 and D7Mit69, which cannot be

resolved at this time, and the distal breakpoint between D7Mit84 and Gabra5.
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Table IV-4. Physical Mapping Data from BACs.

BAC

B36nl0
B4514
B179dl4
B207017
B2lli3
B212f2
B47218
B47222
B142kl0
B142k22
B178nl2
B242212
B279114
B288k21
B315k22
B329d6
B333e23
B34416
B354kl 1
B372f7
B382013
B434210
B462al5

D7

D7

D7

D7

D7

RT

RT

ORN

ORN

Mit
145

Mil

Mit
/94

Mit

Mit

229

230

591/
592

595I
596

607/608
<Bl79dl4end)

609/610
'84514ml

+

+
+

/93

+
+
+

+

+

+

B36n!O/
B2A

B36n!O/
SP6

B36n!O/
T7

B179dl4
end

B179dl4/
BIB

+

+

+

+

+
+
+

+

+

B207
pl7/SP6

B211
i3m

+
+

+

+

+
+
+
+
+
+
+

+
+

+

+

+
+
+

+

+
+
+
+

+

+
+
+

+

+
+

+

+
+

+

+
+
+
+

Note: Molecular markers in the table are not listed in their order along the chromosome. A(+) indicates the marker is present
on theBAC.

/7R/1

ru2

-----------p2MNURf
1--------p3RD300H

1---------pBOK
i---------------pBR250M

Figure IV-5. The Revised psrt Minimal Deletion Interval. The fine-mapping of the
p 3RD 3 ooH deletion enables the map of the minimal deletion interval to be revised to

include the extents of all four p deletions that fail to complement the psrt phenotype:
p

46DFiOD

,p

47DTD

,p

2MNUR/

'

and

p

3RD300H

.

All other deletions that have been tested

complement the phenotype. Therefore, the psrt minimal region, which is represented
by the large gray rectangle, is now defined as the deletion interval bordered proximally
by the proximal breakpoints of both p2MNUR/ and p 3RD 300H, which cannot be resolved at
this time.

The region is bordered distally by the proximal breakpoints of

p8°Kand

.
p 8R250M , wh"1ch a1so cannot b e reso 1ved at th"1s time.
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Table IV-6. Insert Sizes and Notl Restriction Data for Selected BACs.

BAC

Type of
Library

Screened Using Size of Insert

B36n10

PCRpools

D7Mit193

120kb

1

B4514

PCRpools

D7Mit193

120kb

1

B179d14

PCRpools

D7Mit193

150 kb

1

B207p17

PCRpools

D7Mit145

280kb

2

B211i3

PCRpools

D7Mit230

125 kb

1

B212f2

PCRpools

D7Mit145

190 kb

0

Notl
Restriction Sites
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Figure IV-7. Physical Map of the psrt Region of Mouse Chromosome 7. The
centromere of the chromosome is to the left of the diagram, and the telomere is to the
right.

The relevant p deletions are drawn above the chromosome, with the line

representing the area deleted. BACs are drawn below the chromosome and are labeled
with the BAC name and size, if known. The psrt minimal interval is represented by the
bold vertical lines and is labeled at the bottom of the figure.
relevant to this study are represented as colored dots.

Molecular markers

Grey dots are microsatellite

markers, with light grey representing those that have been previously mapped and dark
grey representing those mapped as part of this work. Blue dots represent BAC ends,
yellow dots are STSs generated using single primer PCR, and red dots are expressed
sequences generated from RT-PCR. This map is not drawn to scale.
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Not! Restriction Site

D7Mit193

•1.

l- - .i_:_
►·1~-----I► ◄

..◄---►.i◄Ttp30/Cc3 ►◄
~25 kb

~15 kb

~5 kb

Prmt3

~85 kb

~20kb

Figure V-1. Structure of the Insert of BAC Bl 79dl4. The Tip30/Cc3 and Prmt3
genes are transcribed in the same direction. The Notl restriction site is in the CpG
island near the 5' end of Prmt3, and D7Mit193 is near the 5' end of Tip30/Cc3. The
length of the BAC insert is approximately 150 kb.
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Table V-2. Exon and Intron Sizes for Tip30/Cc3.

EXON#

INTRON#

1
1
2
2
3

3
4
4

5

SIZE (bp)

283+
2300
108
8000
138
1600
62
660
226
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Table V-3. Exon and Intron Sizes for Prmt3.

EXON#

INTRON#

1
1
2
2
3
3
4
4
5
5
6
6
7
7
8
8
9
9
10
10
11

11

12
12
13
13
14
14
15
15
16
16

SIZE (hp)

105+
80
133
1600
83
730
50
770
103
4000
160
1000
142
4600
66
6300
122
8100
10
11400
79
8500
188
1800
87
19100
51
200
88
8400
109
776
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Protein
Methyltransferases

•

Protein
Histidine
Methyltransferases

•

Type I
ro-1'11-monomethylarginine
and (asymmetric)
ro-1'11,1'13-dimethylarginine

RMTl/HMTl
RRP8
PRMTl
PRMT2
PRMT3
PRMT4/CARM1
PRMTS/JBPl

~,
Protein
Arginine
Methyltransferases

+

Type II
w-1'13-monomethylarginine
and (symmetric)
ro-1'11,N
,G_dimethylarginine

MBP-specific
histone-specific

•

Protein
Lysine
Methyltransferases

+

Type III
&-1'13-monomethylarginine

RMT2

Figure VI-I. Protein Methyltransferases.

168

Table VII-1. Primers Used for Standard PCR, RT-PCR and RACE.

Primer
Name
ORN644
ORN645
ORN646
ORN 647
ORN648
ORN663
ORN664
ORN704
ORN723
ORN726
ORN727
ORN728
ORN 772

Primer Sequence (5' - 3')

C

Gene
Prmt3
Prmt3
Prmt3
Prmt3
Prmt3
Ti 30/Cc3
Ti 30/Cc3
Prmt3
Ti 30/Cc3
Ti 30/Cc3
Ti 30/Cc3
Ti 30/Cc3

Corresponding
b ofcDNA
554-573
712-693
1166-1185
1238-1219
1751-1735
1-20
1059-1039
(-18 - (-6)
305-323
323-305
596-614
614-596
632-609
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Prmt3 cDNA

-18 -6

554 573

693 712

II

II

II

1166 1185 -1219 1238

II

II

1735 1751

II

ORN 646/648 (586 bp)

ORN 645/704 (569 hp)

ORN 646/677 (424 bp)

ORN 704/722 (463 bp)

ORN 648/676 (251 bp)

ORN 645/719 (283 bp)

ORN 644/647 (685 hp)
ORN 644/660 (204 bp)
ORN 647/661 (530 bp)

Figure VII-2. Prmt3 cDNA Fragments Used for Heteroduplex Analysis. The Prmt3
cDNA is represented by the long horizontal line at the top of the figure, and the
numbers refer to the nucleotides corresponding to some of the PCR primers. (The start
codon is at position 1.) The shorter, horizontal lines in lighter print are the smaller RTPCR amplification fragments analyzed using TGCE. These fragments range in size
from 204 bp to 530 bp. The darker horizontal lines below the cDNA are the original
RT-PCR fragments used for sequence analysis, which range in size from 569 to 685 bp.
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Figure VII-3.

RT-PCR Analysis of the Tip30/Cc3 cDNA.

(a) The cDNA is

represented by the numbered horizontal line near the top of the figure, numbered so that
hp 1 is the first nucleotide of the start codon. Three sets of primers, represented by the
numbered arrows, were used to amplify overlapping fragments for sequence analysis.
The horizontal lines at the bottom of the figure represent the amplification fragments.
(b) RT-PCR amplification products run on ethidium bromide-stained agarose gels. A
single primer pair (ORN 663/664) was used to amplify a 1060 hp fragment representing
the entire Tip30/Cc3 coding sequence for expression analysis.

The mutants and

controls show no size difference. A 520 hp amplification fragment from (3-actin,
amplified using primers ORN 559/560, was the control.
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(a)

1 20

305 323

I...
I

596 614

846 864

1039 1059

II

...

II

II

728

726

664

I...
I

.. ..

..

723

663

727

ORN 663/728 (615 bp)
ORN 664/727 (464 bp)
ORN 723/726 (560 bp)
ORN 663/664 (1060 bp)

(b)
723SJ

1060SJ BJR

+

+

-

-

+

._

._

ORN 663/664
(1060 bp)

'3-actin
ORN 559/560
(586 bp)

Figure VII-3. RT-PCR Analysis of the Tip30/Cc3 cDNA.
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1

2

3

4

5

6

7

8

9 10 11 12 13

..-oRN
663/664
(1060 bp)

+---- {3-actin
(520 bp)

1 = heart
2 = brain
3 = spleen
4 = lung
5 = liver
6 = skeletal muscle
7 = kidney

Figure VII-4.

8 = testis
9 = 7-day embryo
10 = 11-day embryo
11 = 15-day embryo
12 = 17-day embryo
13 =(-)control

Tip30/Cc3 Multiple Tissue Expression Analysis.

Primers ORN

663/664 were used with cDNAs from the mouse multiple tissue panel to amplify a 1060
hp fragment of the Tip30/Cc3 cDNA containing the entire coding sequence. A single
band of the expected length was detected in all tissues analyzed. A 520 hp fragment
from {3-actin, amplified using primers ORN 559/560, was the control.
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Figure VII-5. RT-PCR Analysis of the Prmt3 cDNA. (a) The cDNA is represented
by the numbered horizontal line near the top of the figure, numbered so that bp 1 is the
first nucleotide of the start codon. Three sets of primers, represented by the numbered
arrows, were used to amplify overlapping fragments for sequence analysis.

The

horizontal lines at the bottom of the figure represent the amplification fragments. (b)
RT-PCR amplification products run on ethidium bromide-stained agarose gels. The
mutants and controls show no size difference in the bands; however, the 723SJ cDNA
produces no amplification product with the ORN 645/704 primers.

A 520 bp

amplification fragment from {3-actin,amplified using primers ORN 559/560, was the
control.
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(a)

.. I..I I..I I..I I..I I..I

-18 -6

554 573

1219 1238

1166 1185

693 712

1735 1751

II

644

704

646

645

647

648

ORN 645/704 (569 hp)
ORN 644/647 (685 hp)
ORN 646/648 (586 hp)

(b)
723SJ

1060SJ

BJR

+

+

+

-

-

..._ ORN 645/704
(569 hp)
..._ ORN 644/647
(685 hp)
..._ ORN 646/648
(586 hp)

{3-actin

+-- ORN 559/560
(586 hp)

Figure VII-5. RT-PCRAnalysis ofthePrmt3 cDNA.
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6

7

8

9

10

11
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12 13

..._ ORN 646/648
(586 bp)

{3-actin
(520 bp)
1 = heart
2 = brain
3 = spleen
4 = lung
5 = liver
6 = skeletal muscle
7 = kidney

8 = testis
9 = 7-day embryo
10 = 11-day embryo
11 = 15-day embryo
12 = 17-day embryo
13 =(-)control

Figure VII-6. Prmt3 Multiple Tissue Expression Analysis. Primers ORN 646/648
were used with cDNAs from the mouse multiple tissue panel to amplify a 586 bp
fragment from the 3' end of the Prmt3 cDNA. A band of the expected length was seen
is all tissues analyzed, and a second, larger band is seen in skeletal muscle and possibly
in heart. A 520 bp fragment from {3-actin,amplified using primers ORN 559/560, was
the control.
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723SJ
m

C

1060SJ
m

C

7.46-kb
4.40-kb

2.37-kb

._2.4kb

1.35-kb

Figure VII-7. Northern Blot of Mutant and Control Brains Probed with a Prmt3
Probe. This blot contains total RNAs from the brains of psrt mutants (m) and nonmutant littermate controls (c) from both the 723SJ (genotype ru2 ++I Df [ru2-p]) and
1060SJ (genotype++ p I Df[ru2-p]) mutant stocks. Df[ru2-p] represents the p 46DFiOD
deletion. The blot was probed with a RT-PCR fragment representing the 5' end of the
Prmt3 cDNA (ORN 645/704). The 723SJ mutant transcript appears to be slightly

shorter than the other transcripts.
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Table VII-8.

Restriction Data for DNA Used in the Genomic Southern Blot

(Figure VII-9).

Enzyme
BstXI
EcoRI
Pstl
Taql

# restriction sites

13
5
20
9

Smallest fragment
39
3287
29
992

Largest fragment
4966
5979
3735
5258

These data represent 25-kb of genomic DNA, from 5-kb upstream of the start codon of
Prmt3 to 20-kb downstream.
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Enzyme:
DNA:

Pstl

Taql

EcoRI

BstXI.

a b c

a b c

a b c

a

b

4000bp~
3000bp~

2000bp~
1650bp~
l000bp~
850bp~
650bp~

a = 723SJ psrt homozygote
b = BJR control
c = 1060SJ psrt homozygote

Figure VII-9. Autoradiograph from a Genomic Southern Blot of psrt mutants.
The blot was probed with 5' end of the prmt3 cDNA. Listed above the photograph are
the enzymes used for digestion and a representation for the genomic DNA present in
each lane. To the left of the photograph are arrows corresponding to the size markers
from the 1-kb plus DNA ladder (not shown). The legend for the DNAs is below the
photograph.

This blot shows no evidence of a genomic rearrangement or deletion.
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(a)

(c)

(b)

(d)

Figure VII-10. Electropherograms from the TGCE Analysis of the psrt Mutants.
(a) The RT 646/677 fragment from the BJR control and the (b) 723SJ psrt homozygote
mixed with the BJR control. There is a single large peak in electropherogram (a) and
two smaller peaks to the right of the main peak in (b). (c) The RT 648/676 fragment
from the BJR control and the (d) 1060SJ psrt homozygote. There is a single large peak
in electropherogram (c) and a smaller peak that appears as a distinct "shoulder" to the
right of the main peak in (b). The multiple peaks present in both (b) and (d) indicate a
mismatch between the control and mutant cDNAs.
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Prmt3cDNA
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1590

1751

I
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II
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ORN 646/648 (586 bp) ;-:-------;,-------.---------3' end of Prmt3 cDNA
ORN 646/677 (424 bp)

ORN 648/676 (251 bp)
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I
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:~utatio~
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:◄

1060SJ
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Figure VII-11. Prmt3 RT-PCR Fragments Containing Mismatches. Mismatches

were detected in both the ORN 646/677 and the ORN 648/676 fragments for the 723SJ
strain, indicating that the mut~tion is most likely in the 89 bp of sequence that overlaps
in those two fragments. A mismatch was detected only in the ORN 648/676 fragment
in the 1060SJ strain, indicating that the mutation is most likely in the 162 bp of
sequence that is contained only in the ORN 648/676 fragment.
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peak area
3.5E+08

glycine

3.0E+08

D lysine

is.

tyrosine
~Me-R

2.5E+08
2.0E+08
l.5E+08
l.0E+08
5.0E+07
0.0E+00
50 ng

100 ng

200 ng

300ng

Mass of amino acid

Figure VIII-1. Calibration Curves for Amino Acid Standards. The concentration
of these four amino acids in a sample can be determined by extrapolation if the
corresponding peak area is known.

Table VIII-2. Extrapolated Quantitation Data.

Sample
psrt
mutantsa
non-psrt
b
controls

Lysine Peak
Area

Lysine
Quantity

Me-RPeak

Me-R

Area

Quantity

Tyrosine
Peak Area

Tyrosine
Quantity

41,414,848

~lOOng

NIA

NIA

13,242,394

~25 ng

87,584,333

~200ng

3,523,593

~100 ng

57,284,175

~75 ng

a The pooled mutant sample class included five homozygotes (genotype ru2 mp I ru2 mp) and
two hemizygotes (genotype ru2 mp I D}Iru2-p])
b

The pooled control sample class included five wild-type animals (genotype ru2 + + I + + p)

and two non-carrier ru2 animals (genotype ru2 + + I ru2 + +)
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Figure VIII-3. Total Ion Chromatographs of MBP Hydrolysate from Control and
Mutant Animals. Chromatographs from age-matched (a) 1060S1 control animals, and
(b) 1060SJ psrt mutant animals. The genotypes of these animals are noted in Table
Vill-2.

The circled regions represent the area surrounding the Me-R peak, which is

identified by its retention time and its mass spectrum.

This peak is missing in the

chromatograph from the mutant animal. An expanded view of the circled regions can
be found in Figure VID-4.
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Figure VIII-4.

Expanded View of the Me-R Region of the Total Ion

Chromatographs of MBP Hydrolysate from Control and Mutant Animals.
Chromatographs from age-matched (a) 1060SJ control animals, and (b) 1060SJ psrt
mutant animals. The genotypes of these animals are noted in Table VIII-2. The circled
regions represent the Me-R peak, which was identified by its retention time and its mass
spectrum. This peak is not present in the chromatograph from the mutant animal.
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